Gaxos.ai (GXAI) S-1 23 Jan 25 IPO registration Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2024
Document Information Line Items
Entity Central Index Key	0001895618
Document Type	S-1
Entity Registrant Name	GAXOS.AI INC.
Entity Incorporation, State or Country Code	DE
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash	$ 5,227,894	$ 1,024,710	$ 679,781
Short-term investments, at fair value	1,416,056	2,592,689
Investment in equity securities, at fair value	199,998
Accounts receivable		8
Prepaid expenses and other current assets	86,609	25,132	400
Deferred offering costs			202,599
Total Current Assets	6,930,557	3,642,539	882,780
LONG-TERM ASSETS:
Property and equipment, net	56,380	52,606
Digital currencies	37	801
Intangible assets, net	132,500		58,647
Total Long-Term Assets	188,917	53,407	58,647
TOTAL ASSETS	7,119,474	3,695,946	941,427
CURRENT LIABILITIES:
Accounts payable	329,288	215,882	245,011
Accrued expenses	73,243	54,154	10,683
Deferred revenue	2,376
Total Current Liabilities	404,907	270,036	255,694
Total Liabilities	404,907	270,036	255,694
Commitments and Contingencies (See Note 7)
STOCKHOLDERS’ EQUITY:
Preferred stock value
Common stock value	189	99	87
Additional paid-in capital	14,668,396	8,711,550	2,119,073
Accumulated other comprehensive income	13,299	95,785
Accumulated deficit	(7,967,317)	(5,381,524)	(1,433,427)
Total Stockholders’ Equity	6,714,567	3,425,910	685,733
Total Liabilities and Stockholders’ Equity	$ 7,119,474	$ 3,695,946	$ 941,427

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock ,par value (in Dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock ,shares authorized	50,000,000	50,000,000	50,000,000
Common stock ,shares issued	1,892,773	988,368	868,154
Common stock ,shares outstanding	1,892,773	988,368	868,154

Statements of Operations and Co

Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
REVENUES	$ 2,704		$ 2,723		$ 256
OPERATING EXPENSES:
Research and development	252,657	258,405	684,327	630,574	915,818	824,523
General and administrative	655,916	615,211	2,122,607	2,501,612	3,047,360	599,573
Impairment loss				52,363	52,363
Total Operating Expenses	908,573	873,616	2,806,934	3,184,549	4,015,541	1,424,096
LOSS FROM OPERATIONS	(905,869)	(873,616)	(2,804,211)	(3,184,549)	(4,015,285)	(1,424,096)
OTHER INCOME:
Interest income	39,409	16,557	96,653	37,415	46,526	2,924
Realized gain on short-term investments	2,050		121,765		20,662
Total other income	41,459	16,557	218,418	37,415	67,188	2,924
NET LOSS	(864,410)	(857,059)	(2,585,793)	(3,147,134)	(3,948,097)	(1,421,172)
COMPREHENSIVE LOSS:
Net loss	(864,410)	(857,059)	(2,585,793)	(3,147,134)	(3,948,097)	(1,421,172)
Other comprehensive gain:
Unrealized (loss) income on short-term investments	9,884	41,841	(82,486)	79,646	95,785
Comprehensive loss	$ (854,526)	$ (815,218)	$ (2,668,279)	$ (3,067,488)	$ (3,852,312)	$ (1,421,172)
NET LOSS PER COMMON SHARE:
Basic (in Dollars per share)	$ (0.61)	$ (0.85)	$ (1.95)	$ (3.2)	$ (4)	$ (1.64)
Diluted (in Dollars per share)	$ (0.61)	$ (0.85)	$ (1.95)	$ (3.2)	$ (4)	$ (1.64)
WEIGHTED AVERAGE COMMON SHARE OUTSTANDING:
Basic (in Shares)	1,418,506	1,005,979	1,329,259	984,625	987,938	868,154
Diluted (in Shares)	1,418,506	1,005,979	1,329,259	984,625	987,938	868,154

Statements of Changes in Stockh

Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Subscription Receivable	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance at Dec. 31, 2021		$ 87	$ 2,119,073	$ (37,500)		$ (12,255)	$ 2,069,405
Balance (in Shares) at Dec. 31, 2021		868,154
Proceeds from subscriptions receivable				37,500			37,500
Net loss						(1,421,172)	(1,421,172)
Balance at Dec. 31, 2022		$ 87	2,119,073			(1,433,427)	685,733
Balance (in Shares) at Dec. 31, 2022		868,154
Common shares and warrants issued for cash, net		$ 14	5,755,857				5,755,871
Common shares and warrants issued for cash, net (in Shares)		140,563
Accretion of stock option expense			870,572				870,572
Accumulated other comprehensive gain - short-term investments					18,156		18,156
Net loss						(1,536,031)	(1,536,031)
Balance at Mar. 31, 2023		$ 101	8,745,502		18,156	(2,969,458)	5,794,301
Balance (in Shares) at Mar. 31, 2023		1,008,717
Balance at Dec. 31, 2022		$ 87	2,119,073			(1,433,427)	685,733
Balance (in Shares) at Dec. 31, 2022		868,154
Net loss							(3,147,134)
Balance at Sep. 30, 2023		$ 91	8,739,656		79,646	(4,580,561)	4,238,832
Balance (in Shares) at Sep. 30, 2023		902,786
Balance at Dec. 31, 2022		$ 87	2,119,073			(1,433,427)	685,733
Balance (in Shares) at Dec. 31, 2022		868,154
Common shares and warrants issued for cash, net		$ 14	5,755,857				5,755,871
Common shares and warrants issued for cash, net (in Shares)		140,563
Purchase and cancellation of treasury stock		$ (2)	(99,734)				(99,736)
Purchase and cancellation of treasury stock (in Shares)		(20,349)
Accretion of stock option expense			936,354				936,354
Accumulated other comprehensive gain - short-term investments					95,785		95,785
Net loss						(3,948,097)	(3,948,097)
Balance at Dec. 31, 2023		$ 99	8,711,550		95,785	(5,381,524)	3,425,910
Balance (in Shares) at Dec. 31, 2023		988,368
Balance at Mar. 31, 2023		$ 101	8,745,502		18,156	(2,969,458)	5,794,301
Balance (in Shares) at Mar. 31, 2023		1,008,717
Purchase and cancellation of treasury stock		$ (3)	(24,238)				(24,241)
Purchase and cancellation of treasury stock (in Shares)		(32,048)
Accretion of stock option expense			21,927				21,927
Accumulated other comprehensive gain - short-term investments					19,649		19,649
Net loss						(754,044)	(754,044)
Balance at Jun. 30, 2023		$ 98	8,743,191		37,805	(3,723,502)	5,057,592
Balance (in Shares) at Jun. 30, 2023		976,669
Purchase and cancellation of treasury stock		$ (7)	(25,462)				(25,469)
Purchase and cancellation of treasury stock (in Shares)		(73,883)
Accretion of stock option expense			21,927				21,927
Accumulated other comprehensive gain - short-term investments					41,841		41,841
Net loss						(857,059)	(857,059)
Balance at Sep. 30, 2023		$ 91	8,739,656		79,646	(4,580,561)	4,238,832
Balance (in Shares) at Sep. 30, 2023		902,786
Balance at Dec. 31, 2023		$ 99	8,711,550		95,785	(5,381,524)	3,425,910
Balance (in Shares) at Dec. 31, 2023		988,368
Common shares and warrants issued for cash, net		$ 11	159,049				159,060
Common shares and warrants issued for cash, net (in Shares)		108,000
Purchase and cancellation of treasury stock		$ (1)	(19,601)				(19,602)
Purchase and cancellation of treasury stock (in Shares)		(6,846)
Accretion of stock option expense			15,806				15,806
Accumulated other comprehensive gain - short-term investments					(99,414)		(99,414)
Sale of pre-funded warrants for cash			2,897,924				2,897,924
Rounding shares from reverse split (in Shares)		4,150
Net loss						(912,145)	(912,145)
Balance at Mar. 31, 2024		$ 109	11,764,728		(3,629)	(6,293,669)	5,467,539
Balance (in Shares) at Mar. 31, 2024		1,093,672
Balance at Dec. 31, 2023		$ 99	8,711,550		95,785	(5,381,524)	3,425,910
Balance (in Shares) at Dec. 31, 2023		988,368
Net loss							(2,585,793)
Balance at Sep. 30, 2024		$ 189	14,668,396		13,299	(7,967,317)	6,714,567
Balance (in Shares) at Sep. 30, 2024		1,892,773
Balance at Mar. 31, 2024		$ 109	11,764,728		(3,629)	(6,293,669)	5,467,539
Balance (in Shares) at Mar. 31, 2024		1,093,672
Common shares issued for warrant exercise		$ 11	93				104
Common shares issued for warrant exercise (in Shares)		103,367
Accretion of stock option expense			33,435				33,435
Accumulated other comprehensive gain - short-term investments					7,044		7,044
Net loss						(809,238)	(809,238)
Balance at Jun. 30, 2024		$ 120	11,798,256		3,415	(7,102,907)	4,698,884
Balance (in Shares) at Jun. 30, 2024		1,197,039
Common shares issued for exercise of March 2024 Common Warrants for cash under warrants inducement offer, net		$ 27	2,834,816				2,834,843
Common shares issued for exercise of March 2024 Common Warrants for cash under warrants inducement offer, net (in Shares)		278,734
Common shares issued for Pre-funded warrant exercises		$ 42	375				417
Common shares issued for Pre-funded warrant exercises (in Shares)		417,000
Accretion of stock option expense			34,949				34,949
Accumulated other comprehensive gain - short-term investments					9,884		9,884
Net loss						(864,410)	(864,410)
Balance at Sep. 30, 2024		$ 189	$ 14,668,396		$ 13,299	$ (7,967,317)	$ 6,714,567
Balance (in Shares) at Sep. 30, 2024		1,892,773

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,585,793)	$ (3,147,134)	$ (3,948,097)	$ (1,421,172)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization expense	37,036	6,968	10,649	4,189
Stock-based compensation	84,190	914,426	936,354
Realized gain on short-term investments	(121,765)		(20,662)
Non-cash transaction fees	764
Impairment loss		52,363	52,363
Change in operating assets and liabilities:
Accounts receivable	8		(8)
Prepaid expenses and other current assets	(61,477)	(79,319)	(24,732)	(400)
Accounts payable	113,406	(65,967)	(29,930)	148,761
Accrued expenses	19,089	10,966	43,471	8,197
Deferred revenue	2,376
NET CASH USED IN OPERATING ACTIVITIES	(2,512,166)	(2,307,697)	(2,980,592)	(1,260,425)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short-term investments	(2,096,293)	(3,491,242)	(3,491,242)
Purchase of marketable equity securities	(199,998)
Proceeds from sale of short-term investments	3,312,205		1,015,000
Increase in capitalized internal-use software development costs	(23,310)	(24,625)	(56,971)
Purchase of intangible asset	(150,000)			(62,836)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	842,604	(3,515,867)	(2,533,213)	(62,836)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the sale of common stock units	159,060	5,958,470	5,958,470
Proceeds from exercise of pre-funded warrants	521
Proceeds from sale of pre-funded warrants	2,897,924
Proceeds from induced exercise of warrants	2,834,843
Proceeds from subscriptions receivable				37,500
Payment of deferred offering costs				(112,599)
Purchase and cancellation of treasury shares	(19,602)	(49,710)	(99,736)
NET CASH PROVIDED BY FINANCING ACTIVITIES	5,872,746	5,908,760	5,858,734	(75,099)
NET INCREASE (DECREASE) IN CASH	4,203,184	85,196	344,929	(1,398,360)
CASH, beginning of period	1,024,710	679,781	679,781	2,078,141
CASH, end of period	5,227,894	764,977	1,024,710	679,781
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest
Income taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Reclassification of deferred offering costs to equity		202,599	202,599
Unrealized (loss) income on short-term investments	(82,486)	79,646
Unrealized gain on short-term investments	(82,486)	79,646	95,785
Increase in digital currency and accounts payable		$ 808	801
Deferred offering costs in accounts payable				$ 90,000

Nature of Operations

Nature of Operations	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Nature of Operations [Abstract]
NATURE OF OPERATIONS	NOTE 1 – NATURE OF OPERATIONS Gaxos.ai Inc. (the “Company”) was incorporated in the state of Wyoming on October 27, 2021 (“Inception”). On March 30, 2022, the Company reincorporated to the State of Delaware pursuant to a Plan of Conversion approved by the Board of Directors and a majority of the shareholders. On January 5, 2024, the Company changed its name from The NFT Gaming Company, Inc. to Gaxos.ai Inc. The Company is a technology-based company that is developing applications aimed at redefining the way we utilize artificial intelligence (“AI”) to optimize the user experience. The Company’s flagship product is its gaming platform called “Gaxos” (the “Platform” or “Gaxos Gaming”), created with a vision to develop, design, acquire, and manage conventional games and to combine these games with unconventional game mechanisms, such as the ability for gamers and developers to utilize artificial intelligence to create and design in-game features, as well as to mint unique in-game features, such as skins, characters, weapons, gear, levels, and virtual lands, in the form of non-fungible tokens, or “NFTs,” that will allow users to have unique experiences and more control over in-game assets. Recently, we began to develop a new initiative, Gaxos Health, which is dedicated to revolutionizing personal health and wellness by developing a suite of innovative AI-powered health optimization solutions. On February 28, 2024, a majority of the Company shareholders granted discretionary authority to the Company’s Board of Directors to amend the Company’s Certificate of Incorporation to effect one or more consolidations of the Company’s issued and outstanding shares of common stock, pursuant to which the shares of common stock would be combined and reclassified into on the basis of one share of common stock for each 12 shares of the Company’s common stock then issued and outstanding (the “Reverse Stock Split”). On March 7, 2024, the Company filed a Certificate of Amendment to the Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-12 reverse stock split with respect to the outstanding shares of the Company’s common stock. The Certificate of Amendment and the reverse stock split became effective on March 7, 2024. All share and per share data in the accompanying financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split. On September 23, 2024, the Company formed a wholly-owned subsidiary, RNK Health, LLC (“RNK Health”), a company incorporated under the laws of the State of Delaware as a limited liability company. RNK Health was formed in order to form a partnership and potential relationship with Nekwellness, LLC (“Nekwellness”), a third party, to engage in the proposed business of marketing certain products, including GLP-1 products (GLP-1 is short for glucagon-like peptide-1), TRT (Testosterone replacement therapy) products and other potential products. In October 2024, the Company and Nekwellness entered into an operating agreement (See Note 8 – Subsequent Events).	NOTE 1 – NATURE OF OPERATIONS Gaxos.ai Inc. (formerly The NFT Gaming Company, Inc.) (the “Company”) was incorporated in the state of Wyoming on October 27, 2021 (“Inception”). On March 30, 2022, the Company reincorporated to the State of Delaware pursuant to a Plan of Conversion approved by the Board of Directors and a majority of the shareholders. On January 5, 2024, the Company changed its name from The NFT Gamimg Company, Inc. to Gaxos.ai Inc. The Company develops, designs, acquires, and manages games that offer affordable non-fungible tokens (NFTs) for unique and exclusive features, rewards, and opportunities. In addition to developing proprietary games, the Company’s platform will onboard third-party game publishers and provide access to blockchain and NFT architecture, product experiences, exclusive content, and revenue opportunities. On November 4, 2022, the Company filed a Certificate of Amendment to the Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-1.33 reverse stock split with respect to the outstanding shares of the Company’s common stock. The Certificate of Amendment and the reverse stock split became effective on November 4, 2022. Additionally, on February 28, 2024, a majority of the Company shareholders granted discretionary authority to the Company’s Board of Directors to amend the Company’s Certificate of Incorporation to effect one or more consolidations of the Company’s issued and outstanding shares of common stock, pursuant to which the shares of common stock would be combined and reclassified into on the basis of one share of common stock for each 12 shares of the Company’s common stock then issued and outstanding (the “Reverse Stock Split”). On March 7, 2024, the Company filed a Certificate of Amendment to the Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-12 reverse stock split with respect to the outstanding shares of the Company’s common stock. The Certificate of Amendment and the reverse stock split became effective on March 7, 2024. All share and per share data in the accompanying financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split. On January 9, 2024, the Staff notified the Company that it has not regained compliance with Listing Rule 5550(a)(2) and was not eligible for a second 180-day period (the “Delisting Determination”). Further, unless the Company requested an appeal of the Delisting Determination to a Hearings Panel (the “Panel”), the Company’s securities would be scheduled for delisting from The Nasdaq Capital Market. In early January 2024, the Company submitted a request to the Panel to appeal the Delisting Determination, and on January 16, 2024, the Panel notified the Company that it received the request which stayed the suspension of the Company’s securities and the filing of the Form 25-NSE, pending the Hearing Panel’s final written decision. On March 22, 2024, the Company received written notice from the Panel that the Company regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and the notes are the representation of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“US GAAP”) and have been consistently applied in the preparation of the financial statements. The accompanying unaudited financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Management acknowledges its responsibility for the preparation of the accompanying unaudited financial statements which reflect all adjustments, consisting of normal recurring and non-recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements. These unaudited financial statements should be read in conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 27, 2024. Liquidity Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. On September 30, 2024, the Company had a cash balance of $5,227,894, had short-term investments of 1,416,056, and had working capital of $6,525,650. During the nine months ended September 30, 2024, the Company used net cash in operations of $2,512,166. Until such time that the Company implements its growth strategy, it expects to continue to generate operating losses in the foreseeable future, mostly due to corporate overhead, research and development, and costs of being a public company. The Company believes that its existing working capital and cash on hand will provide sufficient cash to enable the Company to meet its operating needs and debt requirements for the next twelve months from the issuance date of this report. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying unaudited financial statements include the valuation of investments, valuation of intangible assets and other long-lived assets, estimates of deferred tax valuation allowances and the fair value of stock options issued for services. Fair Value Measurements and Fair Value of Financial Instruments The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (the “FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company identified the following assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 820. The three levels of the fair value hierarchy are as follows: ● Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023. September 30, 2024 December 31, 2023 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Short-term investments $ 1,416,056 $ - $ - $ 2,592,689 $ - $ - Equity securities $ - $ - $ 199,998 $ - $ - $ - The Company’s short-term investments are level 1 measurements and are based on the quoted fair value on each date. Investment in Equity Securities, at Fair Value The following table summarizes activity in the Company’s investment in equity securities, at fair value for the periods presented: Nine Months Nine Months 2024 2023 Balance, beginning of period $ - $ - Additions 199,998 - Balance, end of period $ 199,998 $ - On September 30, 2024, equity securities, at fair value consisted of 666,660 shares of common equity securities of one entity, Dragon Interactive Corporation, a security without a readily determinable fair value. On May 16, 2024, the Company purchased 666,660 common shares of Dragon Interactive Corporation for $199,998. Cash and Cash Equivalents For purposes of the statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. The Company has no cash equivalents as of September 30, 2024 and December 31, 2023. The Company’s cash is held at major commercial banks, which may at times exceed the Federal Deposit Insurance Corporation (“FDIC”) limit. To date, the Company has not experienced any losses on its invested cash. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. On September 30, 2024, the Company had approximately $4,709,000 of cash in excess of FDIC limits of $250,000. Accounts receivable The Company adopted ASC 326, “Financial Instruments - Credit Losses” on January 1, 2023 and recognizes an allowance for losses on accounts receivable in an amount equal to the estimated probable losses net of recoveries under the current expected credit loss method. The allowance is based on an analysis of historical bad debt experience, current receivables aging, and expected future write-offs, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. The bad debt expense associated with the allowance for doubtful accounts related to accounts receivable is recognized in general and administrative expenses. As of September 30, 2024 and December 31, 2023, accounts receivable amounted to $0 Short-Term Investments The Company’s portfolio of short-term investments consists of marketable debt securities which are comprised solely of rated U.S. government securities with maturities of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity requirements. These debt securities are classified as current assets in the balance sheets and recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the balance sheet and as a component of the statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are reported in other income (expense), net in the statements of operations. An impairment loss may be recognized when the decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The Company recorded $(82,486) and $79,646 of unrealized (loss) income on short-term investments as a component of other comprehensive loss for the nine months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company recognized a gain on sale of short-term investments of $121,765 and $0 Investment in Equity Securities, at Fair Value Equity investments are carried at fair value with unrealized gains or losses which are recorded as net unrealized gain (loss) on equity investments in the accompanying statement of operations and comprehensive loss. Realized gains and losses are determined on a specific identification basis which is recorded in earnings or loss as a net realized gain (loss) on equity investments in the statement of operations and comprehensive loss. The Company reviews investments in equity securities, at fair value, for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recovered. Accounting for Digital Currencies and Other Digital Assets The Company accounts for digital currencies and other digital assets as indefinite-lived intangible assets and accounts for them at historical cost in accordance with ASC 350, Intangibles - Goodwill and Other Intangible Assets Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Property and equipment includes capitalized internal-use software development costs. Costs incurred to develop internal-use software, including game development, are expensed as incurred during the preliminary project stage. Internal-use software development costs are capitalized during the application development stage, which is after: (i) the preliminary project stage is completed; and (ii) management authorizes and commits to funding the project and it is probable the project will be completed and used to perform the function intended. Capitalization ceases at the point the software project is substantially complete and ready for its intended use, and after all substantial testing is completed. Upgrades and enhancements are capitalized if it is probable that those expenditures will result in additional functionality. Amortization is provided for on a straight-line basis over the expected useful life of the internal-use software development costs and related upgrades and enhancements, which currently is three years. When existing software is replaced with new software, the unamortized costs of the old software are expensed when the new software is ready for its intended use. Intangible Assets Intangible assets, consisting of software licenses and technology licenses, are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful life of 5 years, less any impairment charges. Stock-based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation–Stock Compensation Income Taxes Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Applicable interest and penalties associated with unrecognized tax benefits are classified as additional income taxes in the statements of operations. Revenue Recognition The Company follows Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). This standard establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASC 606 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. In accordance with ASU Topic 606 - Revenue from Contracts with Customers Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company plans to generate revenue from the following sources: ● The Company generates revenue from the sale of our in-game items to our customers. Revenue generated from such sales, primarily through the app stores, such as Google Play Store or Apple App Store, is recognized upon delivery of the in-game items to the customer, which is when the Company completes its sole performance obligation. Fees incurred by the Company, such as commissions to the app stores, are recognized in operating expenses. ● The Company generates revenue from the sale of health coaching packages to its customers. Health coaching packages consist of a series of lab tests and personal health coaching sessions. Revenues generated from such sales are recognized upon the completion of lab testing and the utilization of health coaching sessions, which is when the Company completes its performance obligation. Any fees paid in advance by the customer are reflected as a contract liabilities until such time as the performance obligation is completed. Fees incurred by the Company, such as the lab testing charges, are recognized in operating expenses. ● The Company plans to generate revenue from advertising fees paid by game advertisers, developers, hardware companies, or other strategic partners to the Company for promotion on our platform. Revenues from these fees will be recognized ratably over the agreed upon advertising service period and upon delivery of agreed upon advertising services, which constitutes satisfaction of the performance obligation. ● The Company plans to generate royalty revenues when a third party sells one of our NFTs on a third-party platform. We will recognize royalty revenue when it is probable that we will collect the royalty fee owed which is typically when we receive notification from the third-party platform that an NFT has been sold, which constitutes satisfaction of the performance obligation. In the instance where the Company will receive royalty payments when a customer disposes of an in-game NFT in the secondary market on a third-party platform or any other payment that is not in fiat currency, the Company will recognize the revenue in accordance with ASC 606-10-32-21, “ Noncash Consideration” Research and Development Research and development costs incurred in the development of the Company’s products are expensed as incurred and include costs such as labor and outside development costs, software license fees, materials, and other allocated costs incurred. Net Loss per Share The Company computes net loss per share in accordance with ASC 260-10, “Earnings Per Share.” “as if converted” Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period presented. Diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. For the three and nine months ended September 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact on the Company’s net loss. September 30, 2024 2023 Common stock equivalents: Warrants 2,666,096 11,245 Stock options 64,084 38,333 Total 2,730,180 49,578 Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation This summary of significant account policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and the notes are the representation of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“US GAAP”) and have been consistently applied in the preparation of the financial statements. The accompanying financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. On December 31, 2023, the Company had a cash balance of $1,024,710, had short-term investments of $2,592,689, and had working capital of $3,372,503. On February 17, 2023, the Company completed an initial public offering (“IPO”) and sold 140,563 shares of its common stock at a price to the public of $49.80 per share for gross proceeds of $7,000,000. The Company received net proceeds of $5,958,470 which is net of offering related expenses paid with proceeds of $1,041,530. The Company also reclassified $202,559 of deferred offering costs as of December 31, 2022 to additional paid in capital upon completing the IPO which resulted in total net proceeds, after equity issuance costs, of $5,755,871. During the year ended December 31, 2023, the Company used net cash in operations of $2,980,592 and purchased liquid short-term investments of $3,491,242. On March 13, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (“the “Purchaser”) for the issuance and sale in a private placement (the “Private Placement”). In connection with this Private Placement, the Company raised aggregate gross proceeds of $3,499,484 and received net proceeds of $3,056,984, net of offering costs of $382,500 and legal fees of $60,000 (See Note 9). Until such time that the Company implements its growth strategy, it expects to continue to generate operating losses in the foreseeable future, mostly due to corporate overhead, research and development, and costs of being a public company. The Company believes that its existing working capital and cash on hand will provide sufficient cash to enable the Company to meet its operating needs and debt requirements for the next twelve months from the issuance date of this report. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include valuation of intangible assets and other long-lived assets, estimates of deferred tax valuation allowances and the fair value of stock options issued for services. Fair Value Measurements and Fair Value of Financial Instruments The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (the “FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company identified the following assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 820. The three levels of the fair value hierarchy are as follows: ● Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022. December 31, 2023 December 31, 2022 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Short-term investments $ 2,592,689 $ - $ - $ - $ - $ - The Company’s short-term investments are level 1 measurements and are based on the quoted fair value at each date. The carrying amounts reported in the balance sheets for cash, accounts receivable, prepaid expenses and other current assets, deferred offering costs, accounts payable, and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. Cash and Cash Equivalents For purposes of the statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. The Company has no cash equivalents as of December 31, 2023 and 2022. The Company’s cash is held at major commercial banks, which may at times exceed the Federal Deposit Insurance Corporation (“FDIC”) limit. To date, the Company has not experienced any losses on its invested cash. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. On December 31, 2023, the Company had approximately $507,000 of cash in excess of FDIC limits of $250,000. Accounts receivable The Company adopted ASC 326, “Financial Instruments - Credit Losses” on January 1, 2023 and recognizes an allowance for losses on accounts receivable in an amount equal to the estimated probable losses net of recoveries under the current expected credit loss method. The allowance is based on an analysis of historical bad debt experience, current receivables aging, and expected future write-offs, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. The bad debt expense associated with the allowance for doubtful accounts related to accounts receivable is recognized in general and administrative expenses. As of December 31, 2023 and 2022, accounts receivable amounted to $8 and $0 Short-Term Investments The Company’s portfolio of short-term investments consists of marketable debt securities which are comprised solely of rated U.S. government securities with maturities of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity requirements. These debt securities are classified as current assets in the balance sheets and recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the balance sheet and as a component of the statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are reported in other income (expense), net in the statements of operations. An impairment loss may be recognized when the decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The Company recorded $95,785 and $0 $0 Accounting for Digital Currencies and Other Digital Assets The Company accounts for digital currencies and other digital assets as indefinite-lived intangible assets and accounts for them at historical cost in accordance with ASC 350, Intangibles - Goodwill and Other Indefinite-lived intangible assets are not subject to amortization but rather evaluated for impairment annually and more frequently, if events or circumstances change that indicate that it is more likely than not that the asset is impaired (i.e., if an impairment indicator exists). As a result, the Company only recognizes decreases in the value of its digital currencies and other digital assets, and any increase in value will be recognized only upon disposition. The Company plans to dispose of cryptocurrency received as a form of payment into fiat currency and anticipates ownership of cryptocurrency to be minimal. As of December 31, 2023, the Company’s digital currencies consisted of 1,553.37 units of Polygon (MATIC), an Ethereum token. The Company held no such digital currencies as of December 31, 2022. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Property and equipment includes capitalized internal-use software development costs. Costs incurred to develop internal-use software, including game development, are expensed as incurred during the preliminary project stage. Internal-use software development costs are capitalized during the application development stage, which is after: (i) the preliminary project stage is completed; and (ii) management authorizes and commits to funding the project and it is probable the project will be completed and used to perform the function intended. Capitalization ceases at the point the software project is substantially complete and ready for its intended use, and after all substantial testing is completed. Upgrades and enhancements are capitalized if it is probable that those expenditures will result in additional functionality. Amortization is provided for on a straight-line basis over the expected useful life of the internal-use software development costs and related upgrades and enhancements, which currently is three years. When existing software is replaced with new software, the unamortized costs of the old software are expensed when the new software is ready for its intended use. During the years ended December 31, 2023 and 2022, internal-use software development costs of $56,971 and $0 Intangible Assets Intangible assets, consisting of software licenses and technology licenses, are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful life of 5 years, less any impairment charges. During the years ended December 31, 2023 and 2022, the Company recorded an impairment loss of $52,363 and $0 Stock-based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation–Stock Compensation Income Taxes Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Applicable interest and penalties associated with unrecognized tax benefits are classified as additional income taxes in the statements of operations. Revenue Recognition The Company follows Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). This standard establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASC 606 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. In accordance with ASU Topic 606 - Revenue from Contracts with Customers Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company plans to generate revenue from the following sources: ● The Company generates revenue from the sale of our in-game items to our customers. Revenue generated from such sales, primarily through the app stores, such as Google Play Store or Apple App Store, is recognized upon delivery of the in-game items to the customer, which is when the Company completes its sole performance obligation. Fees incurred by the Company, such as commissions to the app stores, are recognized in operating expenses. ● The Company plans to generate revenue from advertising fees paid by game advertisers, developers, hardware companies, or other strategic partners to the Company for promotion on our platform. Revenues from these fees will be recognized ratably over the agreed upon advertising service period and upon delivery of agreed upon advertising services, which constitutes satisfaction of the performance obligation. ● The Company plans to generate royalty revenues when a third party sells one of our NFTs on a third-party platform. We will recognize royalty revenue when it is probable that we will collect the royalty fee owed which is typically when we receive notification from the third-party platform that an NFT has been sold, which constitutes satisfaction of the performance obligation. In the instance where the Company will receive royalty payments when a customer disposes of an in-game NFT in the secondary market on a third-party platform or any other payment that is not in fiat currency, the Company will recognize the revenue in accordance with ASC 606-10-32-21, “ Noncash Consideration” Research and Development Research and development costs incurred in the development of the Company’s products are expensed as incurred and include costs such as labor and outside development costs, software license fees, materials, and other allocated costs incurred. Net Loss per Share The Company computes net loss per share in accordance with ASC 260-10, “Earnings Per Share.” “as if converted” Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period presented. Diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The following were excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact on the Company’s net loss. December 31, 2023 2022 Common stock equivalents: Warrants 11,245 - Stock options 38,333 - Total 49,578 - Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Short-Term Investments and Inve

Short-Term Investments and Investment in Equity Securities	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Short-Term Investments and Investment in Equity Securities [Abstract]
SHORT-TERM INVESTMENTS AND INVESTMENT IN EQUITY SECURITIES	NOTE 3 – SHORT-TERM INVESTMENTS AND INVESTMENT IN EQUITY SECURITIES Short-Term Investments On September 30, 2024, the Company’s short-term investments consisted of the following: Cost Cumulative Fair Value US Treasury bills $ 1,402,757 $ 13,299 $ 1,416,056 Total short-term investments $ 1,402,757 $ 13,299 $ 1,416,056 On December 31, 2023, the Company’s short-term investments consisted of the following: Cost Cumulative Fair Value US Treasury bills $ 2,496,904 $ 95,785 $ 2,592,689 Total short-term investments $ 2,496,904 $ 95,785 $ 2,592,689 Investment in Equity Securities, at Fair Value The following table summarizes activity in the Company’s investment in equity securities, at fair value for the periods presented: Nine Months Nine Months 2024 2023 Balance, beginning of period $ - $ - Additions 199,998 - Balance, end of period $ 199,998 $ - On September 30, 2024, investment in equity securities, at fair value consisted of 666,660 shares of common equity securities of one entity, Dragon Interactive Corporation. On May 16, 2024, the Company purchased 666,660 common shares of Dragon Interactive Corporation for $199,998.	NOTE 3 – SHORT-TERM INVESTMENTS On December 31, 2023, the Company’s short-term investments consisted of the following: Cost Unrealized Fair Value US Treasury bills $ 2,496,904 $ 95,785 $ 2,592,689 Total short-term investments $ 2,496,904 $ 95,785 $ 2,592,689

Property and Equipment

Property and Equipment	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 – PROPERTY AND EQUIPMENT On September 30, 2024 and December 31, 2023, property and equipment consisted of the following: Useful life September 30, December 31, Capitalized internal-use software development costs 3 years $ 80,281 $ 56,971 Less: accumulated amortization (23,901 ) (4,365 ) $ 56,380 $ 52,606 During the nine months ended September 30, 2024 and 2023, internal-use software development costs of $23,310 and $24,625 have been capitalized into property and equipment and are being amortized over 36 months, respectively. For the three months ended September 30, 2024 and 2023, amortization of capitalized internal-use software development costs amounted to $6,690 and $684, respectively. For the nine months ended September 30, 2024 and 2023, amortization of capitalized internal-use software development costs amounted to $19,536 and $684, respectively.	NOTE 4 – PROPERTY AND EQUIPMENT On December 31, 2023 and 2022, property and equipment consists of the following: Useful life December 31, December 31, Capitalized internal-use software development costs 3 years $ 56,971 $ - Less: accumulated amortization (4,365 ) - $ 52,606 $ - For the year ended December 31, 2023, amortization of capitalized internal-use software development costs amounted to $4,365.

Intangible Asset

Intangible Asset	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Intangible Asset [Abstract]
INTANGIBLE ASSET	NOTE 5 – INTANGIBLE ASSET On September 30, 2024 and December 31, 2023, intangible asset consisted of the following: Useful life September 30, December 31, License 5 years $ 150,000 $ - Less: accumulated amortization (17,500 ) - $ 132,500 $ - On August 29, 2022, the Company entered into a Software and Patent License Agreement (the “License Agreement”) with Columbia University (“Columbia”), whereby the Company obtained a license from Columbia with respect to software and intellectual property rights and patents. In connection with the License Agreement, Columbia granted to the Company a royalty-bearing, exclusive, worldwide, non-transferable license under the License Agreement, to discover, develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease licensed products and copy, use, modify, and create derivative works from licensed software and technical information during the term of the License Agreement. On August 9, 2023 and effective August 1, 2023, the Company and Columbia University agreed to the termination of the License Agreement. Based on management’s analysis, the Company determined the Licenses were not commercially viable in the current competitive landscape. The termination of the Agreement will not have any impact on the Company’s future revenues. Accordingly, as of June 30, 2023, the Company wrote off the remaining unamortized book value of the intangible asset of $52,363, and during the three and nine months ended September 30, 2023, the Company recorded an impairment loss of $0 On March 4, 2024, the Company entered into a Purchase Agreement with a third party to acquire certain technology and computer code. The Purchase Agreement grants the Company a perpetual, worldwide, non-exclusive, non-transferable, royalty free, fully paid license to (a) modify and create derivative works from certain technology and related codebase including, but not limited to, “Habit-tracking Module,” “Administrative Panel,” and related computer code. The aggregate purchase price was $150,000 and is included in intangible assets on the accompanying balance sheet. The purchase price of $150,000 was payable in 4 monthly installments of $37,500, beginning on March 15, 2024. For the three months ended September 30, 2024 and 2023, amortization of intangible assets amounted to $7,500 and $6,284, respectively, and for the nine months ended September 30, 2024 and 2023, amortization of intangible assets amounted to $17,500 and $6,284, respectively, which is based on an estimated useful life of 5 years and includes amortization expense related to the License Agreement prior to the impairment loss as discussed above. Amortization of the intangible asset attributable to future periods is as follows: Year ending September 30: Amount 2025 $ 30,000 2026 30,000 2027 30,000 2028 30,000 2029 12,500 $ 132,500	NOTE 5 – INTANGIBLE ASSET On December 31, 2023 and 2022, intangible asset consisted of the following: Useful life December 31, December 31, License 5 years $ - $ 62,836 Less: accumulated amortization - (4,189 ) $ - $ 58,647 On August 29, 2022, the Company entered into a Software and Patent License Agreement (the “License Agreement”) with Columbia University (“Columbia”), whereby the Company obtained a license from Columbia with respect to software and intellectual property rights and patents. In connection with the License Agreement, Columbia granted to the Company a royalty-bearing, exclusive, worldwide, non-transferable license under the licensed software and licensed patents, as defined in the License Agreement, to discover, develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease licensed products and copy, use, modify, and create derivative works from licensed software and technical information during the term of the License Agreement. The licensed documentation, licensed software, and licensed patents will be used facilitate a “certificate of authentication” capability for image and video assets to prevent fraudulent activity. This will allow us to certify the image is unaltered in an externally available and trusted way and for a chain-of-trust architecture to be implemented within our system. The technology will also allow us to add an extra validation layer as well as track manipulation of our NFT assets. This will further provide increased trust in our gaming partners to use our platform and provide additional validation and control of third-party assets integrated into our platform. In consideration of the Licenses granted under this License Agreement, the Company paid or was to pay to Columbia fees and royalties as follows: 1) License Fee: A non-refundable, non-recoverable and non-creditable license fee in the sum of $25,000 was paid to Columbia within 30 days of the effective date of August 29, 2022; 2) Revenue-based Milestone Payments including non-refundable, nonrecoverable and non-creditable milestone payments; 3) Royalties: Non-refundable, non-recoverable and non-creditable running royalty on all Licensed Products that are Sold by Company, its Affiliates and Sublicenses, or as otherwise used in to generate Gross Revenue during the term of this Agreement: 4) Fees and expenses: In connection with the License, the Company paid Columbia $30,704 to cover expenses and paid professional fees of $7,132. These fees and expenses were capitalized into intangible assets on the accompany balance sheets. 5) Win-State Payments: In the event of the Company’s success results in significant shareholder value appreciation after as Initial Financing (“Initial Financing” being the first bona fide equity financing of the Company after the Effective Date that results in gross proceeds to the Company of at least $500,000), the Company will make a number of valuation dependent Win-State Payments” to Columbia in connection with a financing or sale (each such transaction a ‘Transaction”). On August 9, 2023 and effective August 1, 2023, the Company and Columbia University agreed to the termination of the Software and Patent License Agreement between the Company and The Trustees of Columbia University in the City of New York, dated August 29, 2022. Based on management’s analysis, the Company determined the Licenses were not commercially viable in the current competitive landscape. The termination of the Agreement will not have any impact on the Company’s future revenues. Accordingly, as of December 31, 2023, the Company wrote off the remaining unamortized book value of the intangible asset of $52,363, and during the year ended December 31, 2023, the Company recorded an impairment loss of $52,363, which is included in operating expenses on the accompanying statement of operations and comprehensive loss. For the year ended December 31, 2023, amortization of intangible assets, prior to the impairment loss, amounted to $6,284.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Stockholders’ Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 6 – STOCKHOLDERS’ EQUITY Preferred Stock The Company is authorized to issue 5,000,000 shares of its $0.0001 par value preferred stock. The Company’s board of directors will have the authority to fix and determine the relative rights and preferences of preferred shares, as well as the authority to issue such shares, without further stockholder approval. As of September 30, 2024 and December 31, 2023, no Common Stock 2023 Stock Repurchase Plan On March 20, 2023, the Board of Directors of the Company approved a stock repurchase program authorizing the purchase of up to $500,000 of the Company’s common stock until December 31, 2023 (the “2023 Stock Repurchase Program”). On January 1, 2024, the Board of Directors of the Company approved an extension of the 2023 Stock Repurchase Program until March 31, 2024. In connection with the 2023 Stock Repurchase Program, from January 1, 2024 to March 31, 2024, the Company purchased and cancelled 6,846 shares of its common stock for $19,602, or at an average price of $2.86 per share, and during the nine months ended September 30, 2023, the Company purchased and cancelled 105,931 shares of its common stock for $49,710, or at an average price of $0.469 per share Initial Public Offering On February 17, 2023, the Company completed the IPO and sold 140,563 shares of its common stock at a price to the public of $49.80 per share for gross proceeds of $7,000,000. The Company received net proceeds of $5,958,470 which is net of offering expenses of $1,041,530. Additionally, the Company reclassified deferred offering costs of $202,599 which were paid and deferred as of December 31, 2022 as a charge to additional paid in capital as equity issuance costs. In connection with the IPO, the Company issued 11,245 warrants to the placement agent. The warrants are exercisable at $54.78 per share and expire on February 14, 2028. The fair value of these warrant of $3,657,258 was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: dividend yield of 0%; expected volatility of 69.8%; risk-free interest rate of 4.03%; and an estimated holding period of 5 years. These warrants had no financial statement impact as they were considered to be equity issuance costs. Capital Raises March 2024 On March 13, 2024, the Company entered into a securities purchase agreement (the “March 2024 Purchase Agreement”) with an institutional investor (“the “Purchaser”) for the issuance and sale in a private placement (the “March 2024 Private Placement”) of aggregate Units consisting of (i) 108,000 shares of the Company’s common stock, (ii) series A warrants to purchase up to 628,367 shares of the Company’s common stock (the “Series A Warrants”), and (iii) series B warrants to purchase up to 628,367 shares of the Company’s common stock (the “Series B Warrants” and together with the Series A Warrants, the “March 2024 Common Warrants”). The purchase price of each Unit consisted of one share of the Company’s common stock and associated March 2024 Common Warrants, was $5.57 per Unit for aggregate gross proceeds of $601,560. Additionally, the Company sold pre-funded warrants to purchase up to 520,367 shares of the Company’s common stock (the “Pre-Funded Warrants”). Pre-funded Warrants are a type of warrant that allows the warrant holder to purchase a specified number of a company’s securities at a nominal exercise price. The purchase price of each Pre-Funded Warrant was $5.569 for aggregate gross proceeds of $2,897,924. In connection with this March 2024 Private Placement, the Company raised aggregate gross proceeds of $3,499,484 consisting of $601,560 from the sales of common stock units and $2,897,924 from the sale of pre-funded warrants, and the Company received net proceeds of $3,056,984, net of offering costs paid to the placement agent (see below) of $382,500 and legal fees of $60,000, which were netted against the $601,560 of gross proceeds from the sale of common stock units for net proceeds allocated to the sale of common stock units of $159,060. The Company is using the net proceeds received from the March 2024 Private Placement for general corporate purposes and working capital. The March 2024 Common Warrants are exercisable immediately upon issuance at an exercise price of $5.50 per share. The Series A Warrants will expire five and one-half years from the date of issuance and the Series B Warrants will expire twenty-four months from the date of issuance. The Pre-Funded Warrants are exercisable immediately upon issuance at a nominal exercise price of $0.001 and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants or March 2024 Common Warrants (together with its affiliates) may not exercise any portion of a warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder 9.99%) of the Company’s outstanding Common Stock immediately after exercise. In connection with the March 2024 Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of March 13, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “ SEC H.C. Wainwright & Co., LLC (“Wainwright”) acted as the Company’s exclusive placement agent in connection with the March 2024 Private Placement, pursuant to that certain engagement letter, dated as of March 7, 2024 and as amended on March 13, 2024, between the Company and Wainwright (the “Engagement Letter”). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a total cash fee equal to 7.5% of the aggregate gross proceeds of the March 2024 Private Placement and (ii) a management fee of 1.0% of the aggregate gross proceeds of the March 2024 Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued to Wainwright or its designees warrants (the “March 2024 Placement Agent Warrants”) to purchase up to an aggregate of 47,128 shares of the Company’s common stock at an exercise price equal to $6.9625 per share. The March 2024 Placement Agent Warrants are exercisable immediately upon issuance and have a term of exercise equal to five and a half years from the date of issuance. The fair value of the March 2024 Placement Agent Warrants of $318,900 was calculated using the Binomial Lattice valuation model, which is considered an offering cost and is netted against the net proceeds received. In addition, pursuant to the Engagement Letter, the Company agreed that upon any exercise for cash of any privately placed warrants issued to investors in an offering covered by the Engagement Letter, the Company shall (i) pay Wainwright a cash fee of 7.5% and a management fee of 1.0% of the aggregate gross exercise paid in cash with respect thereto, and (ii) issue warrants to purchase that number of shares of common stock equal to 7.5% of the aggregate number of shares of common stock underlying the warrants that were exercised. The March 2024 Placement Agent Warrants were valued on the date of issuance using Binomial Lattice valuation model with the following assumptions: March 15, Dividend rate — % Term (in years) 5.5 years Volatility 186.5 % Risk—free interest rate 4.33 % The risk-free interest rate is based on the U.S. Treasury rates at the date of issuance with a maturity date approximately equal to the expected life at issuance date. Volatility is based on historical and expected future volatility of the Company’s common stock. The Company has not historically issued any dividends and does not expect to in the future. September 2024 On September 20, 2024, the Company entered into an inducement offer agreement with the Holder of the March 2024 Common Warrants to immediately exercise for cash an aggregate 1,256,734 of the March 2024 Common Warrants to purchase shares of the Company’s common stock at a reduced exercise price of $2.58 per share for gross proceeds to the Company of $3,242,374 and the Company received net proceeds of $2,834,843 after deducting placement agent fees of $376,552 and other offering expenses paid by the Company of $30,979. The exercised March 2024 Common Warrants were issued pursuant to a March 2024 Purchase Agreement dated March 13, 2024 by and between the Company and the Holder. Each March 2024 Common Warrant was initially exercisable at an original exercise price of $5.50 per share. As an inducement to such exercise, the Company also agreed to issue new unregistered warrants to purchase new Series A common stock purchase warrants (the “New Series A Warrants”) and new Series B common stock purchase warrants (the “New Series B Warrants”, and together with the Series A Warrants, the “New Warrants”), as described below, to purchase an aggregate of up to 2,513,468 shares of the Company’s common stock (the “New Warrant Shares”) at an exercise price of $2.33 per share. The New Series A Warrants to purchase up to 1,256,734 shares of common stock have a term of five and one-half years from the issuance date, and the New Series B Warrants to purchase up to 1,256,734 shares of common stock have a term of twenty-four months from the issuance date. The Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) to act as its exclusive placement agent in connection with the transactions summarized above and has agreed to pay the Placement Agent a cash fee equal to 7.5% of the gross proceeds received from the Holder’s exercise of its Existing Warrants of $243,178, as well as a management fee equal to 1.0% of the gross proceeds from the exercise of the Existing Warrants of $32,424. Additionally, the Company paid the Placement Agent $85,000 for non-accountable expenses and clearing fees in the amount of $15,950. The Company has also issued to the Placement Agent, or its designees, warrants (the “September 2024 Placement Agent Warrants”) to purchase up to 7.5% of the aggregate number of shares of common stock underlying the Existing Warrants (or Placement Agent Warrants to purchase an aggregate of up to 94,255 shares of common stock), which Placement Agent Warrants have the same terms as the New Series A Warrants except for an exercise price per share equal to 125% of the exercise price of the New Warrants (or $3.225 per share). The amendment to the March 2024 Common Warrants on September 20, 2024 to lower the exercise price thereof and issue new warrants, was considered a modification of the March 2024 Common Warrants under the guidance of ASU 2021-04. The modification is consistent with the “Equity Issuance” classification under that guidance as the reason for the modification was to induce the holders to cash exercise their warrants, resulting in the exercise of the March 2024 Common Warrants on September 20, 2024. On September 20, 2024, in connection with the inducement offer agreement, with the Holder of the March 2024 Common Warrants, the Holder exercised the March 2024 Common Warrants for cash at a reduced exercise price of $2.58 per share resulting in net proceeds to the Company of approximately $2,834,843 as discussed above. In connection with such exercise, the Company was to issue up to 1,256,734 Warrant Shares upon the exercise of the March 2024 Comon Warrants. As of September 30, 2024, 978,000 of the Warrant Shares were held in abeyance and were not reflected as issued and outstanding common shares on the accompanying consolidated balance sheet, in accordance with the terms of the inducement offer agreement. Pursuant to the inducement offer agreement, the Company only issued such number of Warrant Shares to the Holder that would not cause the Holder to exceed the maximum number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance of the Warrant Shares held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with the limitations set forth in the inducement offer agreement, which abeyance shall be evidenced through the March 2024 Common Warrants which shall be deemed prepaid thereafter (including the cash payment in full of the exercise price), and exercised pursuant to a Notice of Exercise in the March 2024 Common Warrants (provided no additional exercise price shall be due and payable). As of September 30, 2024, the Company issued 278,734 Warrant Shares to the Holder, and 978,000 Warrant Shares were held in abeyance for future issuance. Subsequent to September 30, 2024, the 978,000 Warrant Shares held in abeyance were issued (See Note 8). On September 20, 2024, the Company calculated the total fair value of the consideration for the modification of the March 2024 Common Warrants, which includes the incremental fair value of the March 2024 Common Warrants (determined by comparing the fair values immediately prior to and immediately after the modification). The fair values were calculated using the Binomial Lattice valuation model, and the Company determined that the total fair value of the consideration related to the modification of the March 2024 Common Warrants amounted to approximately $297,500, which are considered offering costs and were netted against the net proceeds received by the warrant exercise under the guidance of ASU 2021-04, resulting in both a credit and a charge to additional paid-in capital and therefore no net accounting effect. On September 20, 2024, in connection with the inducement offer agreement issuance of the New Warrants and the September 2024 Placement Agent Warrants, the Company calculated the fair value of such warrants using the Binomial option-pricing model, and the Company determined that the aggregate total fair value of the New Warrants and the September 2024 Placement Agent Warrants amounted to approximately $5,460,000, which are considered offering costs and were netted against the net proceeds received by the warrant exercise under the guidance of ASU 2021-04, resulting in both a credit and a charge to additional paid-in capital and therefore no net accounting effect. The fair value of the March 2024 Common Warrants on the modification date, the fair value of the New Warrants, and the fair value of the September 2024 Placement Agent Warrants were estimated using the Binomial option-pricing model with the following assumptions: September 20, Exercise price $2.33 to $3.225 Term (years) 1.75 to 5.5 Expected stock price volatility 162.4% Risk-free rate of interest 3.48% to 3.55% Common Stock Issued for Pre-Funded Warrant Exercises During the three months ended June 30, 2024, the Company issued 103,367 common shares in connection with the exercise of 103,367 pre-funded warrants for net proceeds of $104. During the three months ended September 30, 2024, the Company issued 417,000 common shares in connection with the exercise of 417,000 pre-funded warrants for net proceeds of $417. Stock Warrants In connection with the IPO, in February 2023, the Company issued 11,245 fully vested warrants to the placement agent. The warrants are exercisable at $54.78 per share and expire on February 14, 2028. The warrants were considered equity issuance costs; therefore, there was no financial statement impact for the grant during the year ended December 31, 2023. On March 13, 2024, in connection with the March 2024 Private Placement, the Company issued an aggregate of 1,256,734 Common Warrants consisting of (i) the Series A Warrants to purchase up to 628,367 shares of the Company’s common stock, and (iii) the Series B Warrants to purchase up to 628,367 shares of the Company’s common stock. Additionally, the Company sold the Pre-Funded Warrants to purchase up to 520,367 shares of the Company’s common stock (See above). Additionally, in connection with the March 2024 Private Placement, the Company issued 47,128 March 2024 placement agent warrants. On September 20, 2024, in connection with the inducement offer agreement discussed above , the Company issued an aggregate of 2,513,468 New Warrants consisting of (i) the Series A Warrants to purchase up to 1,256,734 shares of the Company’s common stock, and (ii) the Series B Warrants to purchase up to 1,256,734 shares of the Company’s common stock. Additionally, the Company issued 94,255 September 2024 placement agent warrants. Warrant activity for the nine months ended September 30, 2024 is summarized as follows: Number of Weighted Weighted Aggregate Balance Outstanding, December 31, 2023 11,245 $ 54.78 4.13 $ - Granted 4,431,952 3.02 - - Exercised (1,777,101 ) 1.82 - - Balance Outstanding, September 30, 2024 2,666,096 $ 2.66 3.55 $ 4,239,093 Exercisable, September 30, 2024 2,666,096 $ 2.66 3.55 $ 4,239,093 2022 Equity Incentive Plan On March 30, 2022, the Company’s Board of Directors authorized and adopted the 2022 Equity Incentive Plan (the “2022 Plan”) and reserved an initial 208,333 shares of common stock for issuance thereunder. The 2022 Plan was approved by shareholders on March 30, 2022. The 2022 Plan’s purpose is to encourage ownership in the Company by employees, officers, directors and consultants whose long-term service the Company considers essential to its continued progress and, thereby, encourage recipients to act in the stockholders’ interest and share in the Company’s success. The 2022 Plan provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units (“RSUs”), and other stock-based awards. Pursuant to the 2022 Plan, there shall be annual increase in the number shares reserved under the 2022 Plan on the first day of each calendar year beginning with the first January 1 following the effective date of the 2022 Plan and ending with the last January 1 during the initial ten-year term of the 2022 Plan, equal to the lesser of (A) five percent (5%) of the Shares outstanding (on an as-converted basis, which shall include Shares issuable upon the exercise or conversion of all outstanding securities or rights convertible into or exercisable for Shares, including without limitation, preferred stock, warrants and employee options to purchase any Shares) on the final day of the immediately preceding calendar year and (B) such lesser number of Shares as determined by the Board; provided, that, shares of Common Stock issued under the 2022 Plan with respect to an Exempt Award shall not count against such share limit. Accordingly, in June 2024, the number of shares reserved under the 2022 Plan was increased by 95,304 to 303,637 reserved shares. Stock Options On February 14, 2023, the Company granted aggregate stock options to purchase 33,333 of the Company’s common stock at an exercise price of $49.80 per share to the Company’s chief executive officer, an executive officer, and employee and consultants pursuant to the 2022 Equity Incentive Plan. The grant date of the stock options was February 14, 2023 and the options expire on February 14, 2033. The options vest as to (i) 28,333 of such options on February 14, 2023; and (ii) the remaining 5,000 options vest quarterly (417 each quarter) beginning on May 14, 2023 and each quarter thereafter through February 14, 2026. The stock options were valued at $1,023,290 on the grant date using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. On March 6, 2023, the Company granted stock options to purchase 5,000 of the Company’s common stock at an exercise price of $49.80 per share to the Company’s board of directors pursuant to the 2022 Equity Incentive Plan. The grant date of the stock options was March 6, 2023 and the options expire on March 6, 2028. The options vest on the one-year anniversary of the stock option grant on March 6, 2024. The stock options were valued at the grant date using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. The stock options were valued at $33,972 on the grant date using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. On March 5, 2024, the Company granted stock options to purchase an aggregate of 6,249 (2,083 stock options to each director) shares of the Company’s common stock at an exercise price of $6.00 per share to the Company’s board of directors pursuant to the 2022 Equity Incentive Plan. The grant date of the stock options was March 5, 2024 and the options expire on March 5, 2029. The options vest on the one-year anniversary of the stock option grant on March 5, 2025. The stock options were valued on the grant date at an aggregate fair value of $33,880 using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. On March 7, 2024, the Company entered into Advisory Board Agreements (the Advisory Agreements”) with three members of the Company’s Medical Advisory Board. In connection with the Advisory Agreements, each medical Board member shall be paid an annual cash fee of $40,000 paid quarterly, and Company shall grant each Medical Advisory Board member stock options to purchase 4,167 shares of the Company’s common stock. On May 28, 2024, the Company granted these options for an aggregate of 12,501 stock options at an exercise price of $3.82 per share to the Company’s Advisory board pursuant to the 2022 Equity Incentive Plan. The grant date of the stock options was May 28, 2024 and the options expire on May 28, 2029. The options vest 25% immediately and the remainder vest quarterly. The stock options were valued on the grant date at an aggregate fair value of $46,124 using a Black-Scholes option pricing model which will be recognized as stock-based professional fees over the vesting period. On July 17, 2024, the Company granted stock options to purchase 7,000 shares of the Company’s common stock at an exercise price of $2.15 per share to ta member of the Medical Advisory Board pursuant to the 2022 Equity Incentive Plan. The grant date of the stock options was July 17, 2024 and the options expire on July 17, 2034. The options vest quarterly (875 each quarter) beginning on October 17, 2024 and each quarter thereafter through October 17, 2026. The stock options were valued at $14,536 on the grant date using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. The stock options were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: Nine Months Ended Nine Months Ended Dividend rate —% —% Term (in years) 3.0 to 6.0 years 3.0 to 6.0 years Volatility 168.9 to 184.6% 68.8% to 71.6% Risk—free interest rate 4.07% to 4.56% 3.95% to 4.00% The expected terms of the options are based on evaluations of historical and expected future employee exercise behavior using the simplified method. The risk-free interest rate is based on the U.S. Treasury rates at the date of grant with maturity dates approximately equal to the expected life at grant date. Volatility is based on historical and expected future volatility of the Company’s common stock. The Company has not historically issued any dividends and does not expect to in the future. During the nine months ended September 30, 2024 and 2023, the Company recognized total stock-based expenses related to stock options of $84,190 and $914,426, respectively, which has been reflected in general and administrative expenses on the statements of operations and comprehensive loss. As of September 30, 2024, a balance of $131,258 remains to be expensed over future vesting periods related to unvested stock options issued for services to be expensed over a weighted average period of 1.19 years. Stock option activity during the nine months ended September 30, 2024 is summarized as follows: Number of Weighted Weighted Balance on December 31, 2023 38,334 $ 49.80 8.49 Granted 25,750 3.90 - Balance on September 30, 2024 64,084 $ 31.35 8.01 Options exercisable on September 30, 2024 38,960 $ 46.11 7.85 Weighted average fair value of options granted during the period - $ 3.67 - On September 30, 2024, the aggregate intrinsic value of options outstanding was $0.	NOTE 6 – STOCKHOLDERS’ EQUITY Preferred Stock The Company is authorized to issue 5,000,000 shares of its $0.0001 par value preferred stock. The Company’s board of directors will have the authority to fix and determine the relative rights and preferences of preferred shares, as well as the authority to issue such shares, without further stockholder approval. As of December 31, 2023 and 2022, no Common Stock In January 2022, subscriptions receivable of $37,500 were collected. 2023 Stock Repurchase Plan On March 20, 2023, the Board of Directors of the Company approved a stock repurchase program authorizing the purchase of up to $500,000 of the Company’s common stock until December 31, 2023 (the “2023 Stock Repurchase Program”). In connection with the 2023 Stock Repurchase Program, during the year ended December 31, 2023, the Company purchased and cancelled 20,349 shares of its common stock for $99,736, or at an average price of $4.90 per share. Initial Public Offering On February 17, 2023, the Company completed the IPO and sold 140,563 shares of its common stock at a price to the public of $49.80 per share for gross proceeds of $7,000,000. The Company received net proceeds of $5,958,470 which is net of offering expenses of $1,041,530. Additionally, the Company reclassified deferred offering costs of $202,599 which were paid and deferred as of December 31, 2022 as a charge to additional paid in capital as equity issuance costs. In connection with the IPO, the Company issued 11,245 warrants to the placement agent. The warrants are exercisable at $54.78 per share and expire on February 14, 2028. The fair value of these warrant of $3,657,258 was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: dividend yield of 0%; expected volatility of 69.8%; risk-free interest rate of 4.03%; and an estimated holding period of 5 years. These warrants had no financial statement impact as they were considered to be equity issuance costs. 2022 Equity Incentive Plan On March 30, 2022, the Company’s Board of Directors authorized and adopted the 2022 Equity Incentive Plan (the “2022 Plan”) and reserved 208,333 shares of common stock for issuance thereunder. The 2022 Plan was approved by shareholders on March 30, 2022. The 2022 Plan’s purpose is to encourage ownership in the Company by employees, officers, directors and consultants whose long-term service the Company considers essential to its continued progress and, thereby, encourage recipients to act in the stockholders’ interest and share in the Company’s success. The 2022 Plan provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units (“RSUs”), and other stock-based awards. Stock Options On February 14, 2023, the Company granted aggregate stock options to purchase 33,333 of the Company’s common stock at an exercise price of $49.80 per share to the Company’s chief executive officer, an executive officer, and employee and consultants pursuant to the 2022 Equity Incentive Plan. The grant date of the stock options was February 14, 2023 and the options expire on February 14, 2033. The options vest as to (i) 28,333 of such options on February 14, 2023; and (ii) the remaining 5,000 options vest quarterly (417 each quarter) beginning on May 14, 2023 and each quarter thereafter through February 14, 2026. The stock options were valued at $1,023,290 on the grant date using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. On March 6, 2023, the Company granted stock options to purchase 5,000 of the Company’s common stock at an exercise price of $49.80 per share to the Company’s board of directors pursuant to the 2022 Equity Incentive Plan. The grant date of the stock options was March 6, 2023 and the options expire on March 6, 2028. The options vest on the one-year anniversary of the stock option grant on March 6, 2024. The stock options were valued at the grant date using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. The stock options were valued at $33,972 on the grant date using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. The stock options were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: risk-free interest rates ranging from 3.95% to 4.0%, expected dividend yield of 0%, expected option term of three to six years using the simplified method, and expected volatilities ranging from 68.8% to 71.6% based on the calculated volatility of comparable companies. During the year ended December 31, 2023, the Company recognized total stock-based expenses related to stock options of $936,354 which has been reflected in general and administrative expenses on the statements of operations and comprehensive loss. A balance of $120,908 remains to be expensed over future vesting periods related to unvested stock options issued for services to be expensed over a weighted average period of 2.1 years. There was no option activity during the year ended December 31, 2022. Option activity for the year ended December 31, 2023 are summarized as follows: Number of Weighted Weighted Balance on December 31, 2022 - $ - - Granted 38,333 49.80 - Balance on December 31, 2023 38,333 $ 49.80 8.49 Options exercisable on December 31, 2023 29,583 $ 49.80 9.13 Weighted average fair value of options granted during the period - $ 27.60 - On December 31, 2023, the aggregate intrinsic value of options outstanding was $0. Stock Warrants In connection with the IPO, the Company issued 11,245 fully vested warrants to the placement agent. The warrants are exercisable at $54.78 per share and expire on February 14, 2028. The warrants were considered equity issuance costs; therefore, there was no financial statement impact for the grant during the year ended December 31, 2023. There was no warrant activity during the year ended December 31, 2022. Warrant activity for the year ended December 31, 2023 are summarized as follows: Number of Warrants Weighted Weighted Aggregate Balance Outstanding, December 31, 2022 - $ - - - Granted 11,245 54.78 - - Balance Outstanding, December 31, 2023 11,245 $ 54.78 4.13 - Exercisable, December 31, 2023 11,245 $ 54.78 4.13 -

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES Employment Agreement On February 17, 2023, the Company entered into an executive employment agreement with Vadim Mats, the Company’s Chief Executive Officer (CEO) in connection with the Company’s initial public offering (the “ IPO	NOTE 7 – COMMITMENTS AND CONTINGENCIES Employment Agreement On February 17, 2023, the Company entered into an executive employment agreement with Vadim Mats, the Company’s Chief Executive Officer (CEO) in connection with the Company’s initial public offering (the “ IPO

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
INCOME TAXES	NOTE 8 – INCOME TAXES The Company accounts for income tax using the liability method prescribed by ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The deferred tax assets on December 31, 2023 and 2022 consist of net operating loss carryforwards and the mandatory capitalization of research and development cost for tax purposes pursuant to Section 174, as revised by the Tax Cuts and Jobs Act (“TCJA”). The TCJA amended Section 174 relating to the federal tax treatment of research or experimental expenditures paid or incurred during the taxable year. The new Section 174 rules require taxpayers to capitalize and amortize specified research and experimental expenditures, including software development, over a period of five years (attributable to domestic research) or 15 years (attributable to foreign research). The net deferred tax asset has been fully offset by a valuation allowance because of the uncertainty of the attainment of future taxable income. As of December 31, 2023 and 2022, components of deferred tax assets and liabilities are as follows: December 31, December 31, Net operating loss carryforward $ 795,489 $ 190,123 Research and development 366,256 204,069 Total deferred tax assets 1,161,745 394,192 Valuation allowance (1,161,745 ) (394,192 ) Net Deferred Tax Assets $ - $ - A reconciliation of the effective tax rate with the statutory Federal income tax rate was as follows for the years ended December 31, 2023 and 2022: For the For the Federal tax benefit at statutory rate (21.0 )% (21.0 )% State tax benefit, net of Federal tax benefit (5.1 )% (6.5 )% Non-deductible expenses 6.2 % - % Change in estimated effective tax rate (1.4 )% - % Change in valuation allowance 21.3 % 27.5 % Effective tax rate 0 % 0 % As of December 31, 2023, the Company had approximately $3,043,768 in net operating loss carry forwards for federal income tax purposes of which $3,043,768 may be carried forward indefinitely subject to annual usage limitations of 80% of taxable income. Generally, these can be carried forward and applied against future taxable income at the tax rate applicable at that time. The Company is currently using a 26.135% effective tax rate for its projected available net operating loss carry-forward. In accordance with FASB ASC 740 “Income Taxes”, valuation allowances are provided against deferred tax assets, if based on the weight of available evidence, some or all of the deferred tax assets may or will not be realized. The Company has evaluated its ability to realize some or all of the deferred tax assets on its balance sheet for the coming year and has established a valuation allowance in the amount of $1,161,745 as of December 31, 2023 due to the uncertainty of generating taxable income. The valuation allowance increased in 2023 by $767,553. The Company does not have any uncertain tax positions or events leading to uncertainty in a tax position. The Company’s 2023, 2022 and 2021 Corporate Income Tax Returns are subject to Internal Revenue Service examination.

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS On September 23, 2024, the Company formed a wholly-owned subsidiary, RNK Health, a company incorporated under the laws of the State of Delaware as a limited liability company. RNK Health was formed in order to form a partnership and potential relationship with Nekwellness to engage in the proposed business of marketing certain products. On October 10, 2024, the Company, RNK Health, and Nekwellness entered into an operating agreement (the “Operating Agreement”) of RNK Health for the regulation and management of the affairs of RNK Health. On October 10, 2024, the Company, the sole member of RNK Health, admitted Nekwellness as a member of RNK Health and accordingly, Nekwellness was granted a 30% membership interest in RNK Health, with the Company reduced to a 70% membership interest. Subsequent to September 30, 2024, 978,000 Warrant Shares held in abeyance were issued.	NOTE 9 – SUBSEQUENT EVENTS Reverse split On February 28, 2024, a majority of the Company shareholders granted discretionary authority to the Company’s Board of Directors to amend the Company’s Certificate of Incorporation to effect one or more consolidations of the Company’s issued and outstanding shares of common stock, pursuant to which the shares of common stock would be combined and reclassified into on the basis of one share of common stock for each 12 shares of the Company’s common stock then issued and outstanding (the “Reverse Stock Split”). On March 7, 2024, the Company filed a Certificate of Amendment to the Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-12 reverse stock split with respect to the outstanding shares of the Company’s common stock. The Certificate of Amendment and the reverse stock split became effective on March 7, 2024. All share and per share data in the accompanying financial statements have been retroactively adjusted to reflect the effect of the Reverse Stock Split. Technology purchase agreement On March 4, 2024, the Company entered into a Purchase Agreement with a third party (the “Seller”) to acquire certain technology and computer code. The Purchase Agreement grants the Company a perpetual, worldwide, non-exclusive, non-transferable, royalty free, fully paid license to (a) modify and create derivative works (“Derivative Works”) from certain technology and related codebase including, but not limited to, “Habit-tracking Module,” “Administrative Panel,” and related computer code (the “Code”). The aggregate purchase price shall be $150,000 (“Purchase Price”) payable in 4 monthly installments of $37,500 beginning on March 15, 2024. Stock options On March 5, 2024, the Company granted stock options to purchase an aggregate of 6,249 (2,083 stock options to each director) shares of the Company’s common stock at an exercise price of $6.00 per share to the Company’s board of directors pursuant to the 2022 Equity Incentive Plan. The grant date of the stock options was March 5, 2024 and the options expire on March 5, 2029. The options vest on the one-year anniversary of the stock option grant on March 5, 2025. The stock options will be valued on the grant date using a Black-Scholes option pricing model which will be recognized as stock-based compensation expense over the vesting period. On March 7, 2024, the Company entered into Advisory Board Agreements (the Advisory Agreements”) with three members of the Company’s Medical Advisory Board. In connection with the Advisory Agreements, each medical Board member shall be paid an annual cash fee of $40,000 paid quarterly, and Company shall grant each Medical Advisory Board member stock options to purchase 4,167 shares of the Company’s common stock. As of the date of this report, the Company has not granted these options. The stock options will be valued on the grant date using a Black-Scholes option pricing model which will be recognized as stock-based professional fees over the vesting period. Private Placement On March 13, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (“the “Purchaser”) for the issuance and sale in a private placement (the “Private Placement”) of aggregate Units consisting of (i) 108,000 shares of the Company’s common stock, (ii) series A warrants to purchase up to 628,367 shares of the Company’s common stock (the “Series A Warrants”), and (iii) series B warrants to purchase up to 628,367 shares of the Company’s common stock (the “Series B Warrants” and together with the Series A Warrants, the “Common Warrants”). The purchase price of each Unit consisted of one share of the Company’s common stock and associated Common Warrants, was $5.57 per Unit for aggregate gross proceeds of $601,560. Additionally, the Company sold pre-funded warrants to purchase up to 520,367 shares of the Company’s common stock (the “Pre-Funded Warrants”). Pre-funded Warrants are a type of warrant that allows the warrant holder to purchase a specified number of a company’s securities at a nominal exercise price. The purchase price of each Pre-Funded Warrant was $5.569 for aggregate gross proceeds of $2,897,924. In connection with this Private Placement, the Company raised aggregate gross proceeds of $3,499,484 and received net proceeds of $3,056,984, net of offering costs of $382,500 and legal fees of $60,000. The Common Warrants are exercisable immediately upon issuance at an exercise price of $5.50 per share. The Series A Warrants will expire five and one-half years from the date of issuance and the Series B Warrants will expire twenty-four months from the date of issuance. The Pre-Funded Warrants are exercisable immediately upon issuance at a nominal exercise price of $0.001 and may be exercised at any time until the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants or Common Warrants (together with its affiliates) may not exercise any portion of a warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder 9.99%) of the Company’s outstanding Common Stock immediately after exercise. In connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of March 13, 2024, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “ SEC The Private Placement closed on March 15, 2024. The gross proceeds to the Company from the Private Placement were approximately $3.5 million, before deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement for general corporate purposes and working capital. H.C. Wainwright & Co., LLC (“Wainwright”) acted as the Company’s exclusive placement agent in connection with the Private Placement, pursuant to that certain engagement letter, dated as of March 7, 2024 and as amended on March 13, 2024, between the Company and Wainwright (the “Engagement Letter”). Pursuant to the Engagement Letter, the Company paid Wainwright (i) a total cash fee equal to 7.5% of the aggregate gross proceeds of the Private Placement and (ii) a management fee of 1.0% of the aggregate gross proceeds of the Private Placement. In addition, the Company agreed to pay Wainwright certain expenses and issued to Wainwright or its designees warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 47,128 shares of the Company’s common stock at an exercise price equal to $6.9625 per share. The Placement Agent Warrants are exercisable immediately upon issuance and have a term of exercise equal to five and a half years from the date of issuance. In addition, pursuant to the Engagement Letter, the Company agreed that upon any exercise for cash of any privately placed warrants issued to investors in an offering covered by the Engagement Letter, the Company shall (i) pay Wainwright a cash fee of 7.5% and a management fee of 1.0% of the aggregate gross exercise paid in cash with respect thereto, and (ii) issue warrants to purchase that number of shares of common stock equal to 7.5% of the aggregate number of shares of common stock underlying the warrants that were exercised. Treasury Shares In connection with the 2023 Stock Repurchase Program, from January 1, 2024 to March 28, 2024, the Company purchased and cancelled 6,846 shares of its common stock for $19,601, or at an average price of $2.86 per share.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and the notes are the representation of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“US GAAP”) and have been consistently applied in the preparation of the financial statements. The accompanying unaudited financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Management acknowledges its responsibility for the preparation of the accompanying unaudited financial statements which reflect all adjustments, consisting of normal recurring and non-recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements. These unaudited financial statements should be read in conjunction with the summary of significant accounting policies and notes to the financial statements for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 27, 2024.	Basis of Presentation This summary of significant account policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and the notes are the representation of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“US GAAP”) and have been consistently applied in the preparation of the financial statements. The accompanying financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. On December 31, 2023, the Company had a cash balance of $1,024,710, had short-term investments of $2,592,689, and had working capital of $3,372,503. On February 17, 2023, the Company completed an initial public offering (“IPO”) and sold 140,563 shares of its common stock at a price to the public of $49.80 per share for gross proceeds of $7,000,000. The Company received net proceeds of $5,958,470 which is net of offering related expenses paid with proceeds of $1,041,530. The Company also reclassified $202,559 of deferred offering costs as of December 31, 2022 to additional paid in capital upon completing the IPO which resulted in total net proceeds, after equity issuance costs, of $5,755,871. During the year ended December 31, 2023, the Company used net cash in operations of $2,980,592 and purchased liquid short-term investments of $3,491,242. On March 13, 2024, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (“the “Purchaser”) for the issuance and sale in a private placement (the “Private Placement”). In connection with this Private Placement, the Company raised aggregate gross proceeds of $3,499,484 and received net proceeds of $3,056,984, net of offering costs of $382,500 and legal fees of $60,000 (See Note 9). Until such time that the Company implements its growth strategy, it expects to continue to generate operating losses in the foreseeable future, mostly due to corporate overhead, research and development, and costs of being a public company. The Company believes that its existing working capital and cash on hand will provide sufficient cash to enable the Company to meet its operating needs and debt requirements for the next twelve months from the issuance date of this report.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying unaudited financial statements include the valuation of investments, valuation of intangible assets and other long-lived assets, estimates of deferred tax valuation allowances and the fair value of stock options issued for services.	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates in the accompanying financial statements include valuation of intangible assets and other long-lived assets, estimates of deferred tax valuation allowances and the fair value of stock options issued for services.
Fair Value Measurements and Fair Value of Financial Instruments	Fair Value Measurements and Fair Value of Financial Instruments The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (the “FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company identified the following assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 820. The three levels of the fair value hierarchy are as follows: ● Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023. September 30, 2024 December 31, 2023 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Short-term investments $ 1,416,056 $ - $ - $ 2,592,689 $ - $ - Equity securities $ - $ - $ 199,998 $ - $ - $ - The Company’s short-term investments are level 1 measurements and are based on the quoted fair value on each date. Investment in Equity Securities, at Fair Value The following table summarizes activity in the Company’s investment in equity securities, at fair value for the periods presented: Nine Months Nine Months 2024 2023 Balance, beginning of period $ - $ - Additions 199,998 - Balance, end of period $ 199,998 $ - On September 30, 2024, equity securities, at fair value consisted of 666,660 shares of common equity securities of one entity, Dragon Interactive Corporation, a security without a readily determinable fair value. On May 16, 2024, the Company purchased 666,660 common shares of Dragon Interactive Corporation for $199,998.	Fair Value Measurements and Fair Value of Financial Instruments The Company analyzes all financial instruments with features of both liabilities and equity under the Financial Accounting Standard Board’s (the “FASB”) accounting standard for such instruments. Under this standard, financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company identified the following assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 820. The three levels of the fair value hierarchy are as follows: ● Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. ● Level 2 - Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. ● Level 3 - Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022. December 31, 2023 December 31, 2022 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Short-term investments $ 2,592,689 $ - $ - $ - $ - $ - The Company’s short-term investments are level 1 measurements and are based on the quoted fair value at each date. The carrying amounts reported in the balance sheets for cash, accounts receivable, prepaid expenses and other current assets, deferred offering costs, accounts payable, and accrued expenses approximate their fair market value based on the short-term maturity of these instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of the statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. The Company has no cash equivalents as of September 30, 2024 and December 31, 2023. The Company’s cash is held at major commercial banks, which may at times exceed the Federal Deposit Insurance Corporation (“FDIC”) limit. To date, the Company has not experienced any losses on its invested cash. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. On September 30, 2024, the Company had approximately $4,709,000 of cash in excess of FDIC limits of $250,000.	Cash and Cash Equivalents For purposes of the statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. The Company has no cash equivalents as of December 31, 2023 and 2022. The Company’s cash is held at major commercial banks, which may at times exceed the Federal Deposit Insurance Corporation (“FDIC”) limit. To date, the Company has not experienced any losses on its invested cash. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows. On December 31, 2023, the Company had approximately $507,000 of cash in excess of FDIC limits of $250,000.
Accounts receivable	Accounts receivable The Company adopted ASC 326, “Financial Instruments - Credit Losses” on January 1, 2023 and recognizes an allowance for losses on accounts receivable in an amount equal to the estimated probable losses net of recoveries under the current expected credit loss method. The allowance is based on an analysis of historical bad debt experience, current receivables aging, and expected future write-offs, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. The bad debt expense associated with the allowance for doubtful accounts related to accounts receivable is recognized in general and administrative expenses. As of September 30, 2024 and December 31, 2023, accounts receivable amounted to $0	Accounts receivable The Company adopted ASC 326, “Financial Instruments - Credit Losses” on January 1, 2023 and recognizes an allowance for losses on accounts receivable in an amount equal to the estimated probable losses net of recoveries under the current expected credit loss method. The allowance is based on an analysis of historical bad debt experience, current receivables aging, and expected future write-offs, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. The bad debt expense associated with the allowance for doubtful accounts related to accounts receivable is recognized in general and administrative expenses. As of December 31, 2023 and 2022, accounts receivable amounted to $8 and $0
Short-Term Investments	Short-Term Investments The Company’s portfolio of short-term investments consists of marketable debt securities which are comprised solely of rated U.S. government securities with maturities of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity requirements. These debt securities are classified as current assets in the balance sheets and recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the balance sheet and as a component of the statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are reported in other income (expense), net in the statements of operations. An impairment loss may be recognized when the decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The Company recorded $(82,486) and $79,646 of unrealized (loss) income on short-term investments as a component of other comprehensive loss for the nine months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024 and 2023, the Company recognized a gain on sale of short-term investments of $121,765 and $0	Short-Term Investments The Company’s portfolio of short-term investments consists of marketable debt securities which are comprised solely of rated U.S. government securities with maturities of more than three months, but less than one year. The Company classifies these as available-for-sale at purchase date and will reevaluate such designation at each period end date. The Company may sell these marketable debt securities prior to their stated maturities depending upon changing liquidity requirements. These debt securities are classified as current assets in the balance sheets and recorded at fair value, with unrealized gains or losses included in accumulated other comprehensive income (loss) on the balance sheet and as a component of the statements of comprehensive loss. Gains and losses are recognized when realized. Gains and losses are determined using the specific identification method and are reported in other income (expense), net in the statements of operations. An impairment loss may be recognized when the decline in fair value of the debt securities is determined to be other-than-temporary. The Company evaluates its investments for other-than-temporary declines in fair value below the cost basis each quarter, or whenever events or changes in circumstances indicate that the cost basis of the short-term investments may not be recoverable. The evaluation is based on a number of factors, including the length of time and the extent to which the fair value has been below the cost basis, as well as adverse conditions related specifically to the security, such as any changes to the credit rating of the security and the intent to sell or whether the Company will more likely than not be required to sell the security before recovery of its amortized cost basis. The Company recorded $95,785 and $0 $0
Accounting for Digital Currencies and Other Digital Assets	Accounting for Digital Currencies and Other Digital Assets The Company accounts for digital currencies and other digital assets as indefinite-lived intangible assets and accounts for them at historical cost in accordance with ASC 350, Intangibles - Goodwill and Other Intangible Assets	Accounting for Digital Currencies and Other Digital Assets The Company accounts for digital currencies and other digital assets as indefinite-lived intangible assets and accounts for them at historical cost in accordance with ASC 350, Intangibles - Goodwill and Other Indefinite-lived intangible assets are not subject to amortization but rather evaluated for impairment annually and more frequently, if events or circumstances change that indicate that it is more likely than not that the asset is impaired (i.e., if an impairment indicator exists). As a result, the Company only recognizes decreases in the value of its digital currencies and other digital assets, and any increase in value will be recognized only upon disposition. The Company plans to dispose of cryptocurrency received as a form of payment into fiat currency and anticipates ownership of cryptocurrency to be minimal. As of December 31, 2023, the Company’s digital currencies consisted of 1,553.37 units of Polygon (MATIC), an Ethereum token. The Company held no such digital currencies as of December 31, 2022.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Property and equipment includes capitalized internal-use software development costs. Costs incurred to develop internal-use software, including game development, are expensed as incurred during the preliminary project stage. Internal-use software development costs are capitalized during the application development stage, which is after: (i) the preliminary project stage is completed; and (ii) management authorizes and commits to funding the project and it is probable the project will be completed and used to perform the function intended. Capitalization ceases at the point the software project is substantially complete and ready for its intended use, and after all substantial testing is completed. Upgrades and enhancements are capitalized if it is probable that those expenditures will result in additional functionality. Amortization is provided for on a straight-line basis over the expected useful life of the internal-use software development costs and related upgrades and enhancements, which currently is three years. When existing software is replaced with new software, the unamortized costs of the old software are expensed when the new software is ready for its intended use.	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method over their estimated useful lives. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Property and equipment includes capitalized internal-use software development costs. Costs incurred to develop internal-use software, including game development, are expensed as incurred during the preliminary project stage. Internal-use software development costs are capitalized during the application development stage, which is after: (i) the preliminary project stage is completed; and (ii) management authorizes and commits to funding the project and it is probable the project will be completed and used to perform the function intended. Capitalization ceases at the point the software project is substantially complete and ready for its intended use, and after all substantial testing is completed. Upgrades and enhancements are capitalized if it is probable that those expenditures will result in additional functionality. Amortization is provided for on a straight-line basis over the expected useful life of the internal-use software development costs and related upgrades and enhancements, which currently is three years. When existing software is replaced with new software, the unamortized costs of the old software are expensed when the new software is ready for its intended use. During the years ended December 31, 2023 and 2022, internal-use software development costs of $56,971 and $0
Intangible Assets	Intangible Assets Intangible assets, consisting of software licenses and technology licenses, are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful life of 5 years, less any impairment charges.	Intangible Assets Intangible assets, consisting of software licenses and technology licenses, are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful life of 5 years, less any impairment charges. During the years ended December 31, 2023 and 2022, the Company recorded an impairment loss of $52,363 and $0
Stock-based Compensation	Stock-based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation–Stock Compensation	Stock-based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation–Stock Compensation
Income Taxes	Income Taxes Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Applicable interest and penalties associated with unrecognized tax benefits are classified as additional income taxes in the statements of operations.	Income Taxes Deferred income taxes are provided using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Applicable interest and penalties associated with unrecognized tax benefits are classified as additional income taxes in the statements of operations.
Revenue Recognition	Revenue Recognition The Company follows Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). This standard establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASC 606 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. In accordance with ASU Topic 606 - Revenue from Contracts with Customers Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company plans to generate revenue from the following sources: ● The Company generates revenue from the sale of our in-game items to our customers. Revenue generated from such sales, primarily through the app stores, such as Google Play Store or Apple App Store, is recognized upon delivery of the in-game items to the customer, which is when the Company completes its sole performance obligation. Fees incurred by the Company, such as commissions to the app stores, are recognized in operating expenses. ● The Company generates revenue from the sale of health coaching packages to its customers. Health coaching packages consist of a series of lab tests and personal health coaching sessions. Revenues generated from such sales are recognized upon the completion of lab testing and the utilization of health coaching sessions, which is when the Company completes its performance obligation. Any fees paid in advance by the customer are reflected as a contract liabilities until such time as the performance obligation is completed. Fees incurred by the Company, such as the lab testing charges, are recognized in operating expenses. ● The Company plans to generate revenue from advertising fees paid by game advertisers, developers, hardware companies, or other strategic partners to the Company for promotion on our platform. Revenues from these fees will be recognized ratably over the agreed upon advertising service period and upon delivery of agreed upon advertising services, which constitutes satisfaction of the performance obligation. ● The Company plans to generate royalty revenues when a third party sells one of our NFTs on a third-party platform. We will recognize royalty revenue when it is probable that we will collect the royalty fee owed which is typically when we receive notification from the third-party platform that an NFT has been sold, which constitutes satisfaction of the performance obligation. In the instance where the Company will receive royalty payments when a customer disposes of an in-game NFT in the secondary market on a third-party platform or any other payment that is not in fiat currency, the Company will recognize the revenue in accordance with ASC 606-10-32-21, “ Noncash Consideration”	Revenue Recognition The Company follows Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). This standard establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASC 606 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. In accordance with ASU Topic 606 - Revenue from Contracts with Customers Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company plans to generate revenue from the following sources: ● The Company generates revenue from the sale of our in-game items to our customers. Revenue generated from such sales, primarily through the app stores, such as Google Play Store or Apple App Store, is recognized upon delivery of the in-game items to the customer, which is when the Company completes its sole performance obligation. Fees incurred by the Company, such as commissions to the app stores, are recognized in operating expenses. ● The Company plans to generate revenue from advertising fees paid by game advertisers, developers, hardware companies, or other strategic partners to the Company for promotion on our platform. Revenues from these fees will be recognized ratably over the agreed upon advertising service period and upon delivery of agreed upon advertising services, which constitutes satisfaction of the performance obligation. ● The Company plans to generate royalty revenues when a third party sells one of our NFTs on a third-party platform. We will recognize royalty revenue when it is probable that we will collect the royalty fee owed which is typically when we receive notification from the third-party platform that an NFT has been sold, which constitutes satisfaction of the performance obligation. In the instance where the Company will receive royalty payments when a customer disposes of an in-game NFT in the secondary market on a third-party platform or any other payment that is not in fiat currency, the Company will recognize the revenue in accordance with ASC 606-10-32-21, “ Noncash Consideration”
Research and Development	Research and Development Research and development costs incurred in the development of the Company’s products are expensed as incurred and include costs such as labor and outside development costs, software license fees, materials, and other allocated costs incurred.	Research and Development Research and development costs incurred in the development of the Company’s products are expensed as incurred and include costs such as labor and outside development costs, software license fees, materials, and other allocated costs incurred.
Net Loss per Share	Net Loss per Share The Company computes net loss per share in accordance with ASC 260-10, “Earnings Per Share.” “as if converted” Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period presented. Diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. For the three and nine months ended September 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact on the Company’s net loss. September 30, 2024 2023 Common stock equivalents: Warrants 2,666,096 11,245 Stock options 64,084 38,333 Total 2,730,180 49,578	Net Loss per Share The Company computes net loss per share in accordance with ASC 260-10, “Earnings Per Share.” “as if converted” Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period presented. Diluted loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The following were excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact on the Company’s net loss. December 31, 2023 2022 Common stock equivalents: Warrants 11,245 - Stock options 38,333 - Total 49,578 -
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.	Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
Liquidity	Liquidity Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. On September 30, 2024, the Company had a cash balance of $5,227,894, had short-term investments of 1,416,056, and had working capital of $6,525,650. During the nine months ended September 30, 2024, the Company used net cash in operations of $2,512,166. Until such time that the Company implements its growth strategy, it expects to continue to generate operating losses in the foreseeable future, mostly due to corporate overhead, research and development, and costs of being a public company. The Company believes that its existing working capital and cash on hand will provide sufficient cash to enable the Company to meet its operating needs and debt requirements for the next twelve months from the issuance date of this report.
Investment in Equity Securities, at Fair Value	Investment in Equity Securities, at Fair Value Equity investments are carried at fair value with unrealized gains or losses which are recorded as net unrealized gain (loss) on equity investments in the accompanying statement of operations and comprehensive loss. Realized gains and losses are determined on a specific identification basis which is recorded in earnings or loss as a net realized gain (loss) on equity investments in the statement of operations and comprehensive loss. The Company reviews investments in equity securities, at fair value, for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recovered.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Schedule of Fair Value Hierarchy of its Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023. September 30, 2024 December 31, 2023 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Short-term investments $ 1,416,056 $ - $ - $ 2,592,689 $ - $ - Equity securities $ - $ - $ 199,998 $ - $ - $ -	The following table represents the Company’s fair value hierarchy of its financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and 2022. December 31, 2023 December 31, 2022 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Short-term investments $ 2,592,689 $ - $ - $ - $ - $ -
Schedule of Computation of Diluted Shares Outstanding as they would have had an Anti-Dilutive Impact on the Company’s Net Loss	For the three and nine months ended September 30, 2024 and 2023, the following common stock equivalents were excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact on the Company’s net loss. September 30, 2024 2023 Common stock equivalents: Warrants 2,666,096 11,245 Stock options 64,084 38,333 Total 2,730,180 49,578	The following were excluded from the computation of diluted shares outstanding as they would have had an anti-dilutive impact on the Company’s net loss. December 31, 2023 2022 Common stock equivalents: Warrants 11,245 - Stock options 38,333 - Total 49,578 -
Schedule of Investment in Equity Securities, at Fair Value for the Periods	The following table summarizes activity in the Company’s investment in equity securities, at fair value for the periods presented: Nine Months Nine Months 2024 2023 Balance, beginning of period $ - $ - Additions 199,998 - Balance, end of period $ 199,998 $ -

Short-Term Investments and In_2

Short-Term Investments and Investment in Equity Securities (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Short-Term Investments and Investment in Equity Securities (Tables) [Line Items]
Schedule of Short-Term Investments	On September 30, 2024, the Company’s short-term investments consisted of the following: Cost Cumulative Fair Value US Treasury bills $ 1,402,757 $ 13,299 $ 1,416,056 Total short-term investments $ 1,402,757 $ 13,299 $ 1,416,056 Cost Cumulative Fair Value US Treasury bills $ 2,496,904 $ 95,785 $ 2,592,689 Total short-term investments $ 2,496,904 $ 95,785 $ 2,592,689	On December 31, 2023, the Company’s short-term investments consisted of the following: Cost Unrealized Fair Value US Treasury bills $ 2,496,904 $ 95,785 $ 2,592,689 Total short-term investments $ 2,496,904 $ 95,785 $ 2,592,689
Schedule of Investment in Equity Securities, at Fair Value for the Periods	The following table summarizes activity in the Company’s investment in equity securities, at fair value for the periods presented: Nine Months Nine Months 2024 2023 Balance, beginning of period $ - $ - Additions 199,998 - Balance, end of period $ 199,998 $ -
Short-Term Investments [Member]
Short-Term Investments and Investment in Equity Securities (Tables) [Line Items]
Schedule of Investment in Equity Securities, at Fair Value for the Periods	The following table summarizes activity in the Company’s investment in equity securities, at fair value for the periods presented: Nine Months Nine Months 2024 2023 Balance, beginning of period $ - $ - Additions 199,998 - Balance, end of period $ 199,998 $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Property and Equipment [Abstract]
Schedule of Property and Equipment	On September 30, 2024 and December 31, 2023, property and equipment consisted of the following: Useful life September 30, December 31, Capitalized internal-use software development costs 3 years $ 80,281 $ 56,971 Less: accumulated amortization (23,901 ) (4,365 ) $ 56,380 $ 52,606	On December 31, 2023 and 2022, property and equipment consists of the following: Useful life December 31, December 31, Capitalized internal-use software development costs 3 years $ 56,971 $ - Less: accumulated amortization (4,365 ) - $ 52,606 $ -

Intangible Asset (Tables)

Intangible Asset (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Intangible Asset [Abstract]
Schedule of Intangible Asset	On September 30, 2024 and December 31, 2023, intangible asset consisted of the following: Useful life September 30, December 31, License 5 years $ 150,000 $ - Less: accumulated amortization (17,500 ) - $ 132,500 $ -	On December 31, 2023 and 2022, intangible asset consisted of the following: Useful life December 31, December 31, License 5 years $ - $ 62,836 Less: accumulated amortization - (4,189 ) $ - $ 58,647
Schedule of Amortization of the Intangible Asset	Amortization of the intangible asset attributable to future periods is as follows: Year ending September 30: Amount 2025 $ 30,000 2026 30,000 2027 30,000 2028 30,000 2029 12,500 $ 132,500

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Stockholders’ Equity [Abstract]
Schedule of Option Activity	Stock option activity during the nine months ended September 30, 2024 is summarized as follows: Number of Weighted Weighted Balance on December 31, 2023 38,334 $ 49.80 8.49 Granted 25,750 3.90 - Balance on September 30, 2024 64,084 $ 31.35 8.01 Options exercisable on September 30, 2024 38,960 $ 46.11 7.85 Weighted average fair value of options granted during the period - $ 3.67 -	There was no option activity during the year ended December 31, 2022. Option activity for the year ended December 31, 2023 are summarized as follows: Number of Weighted Weighted Balance on December 31, 2022 - $ - - Granted 38,333 49.80 - Balance on December 31, 2023 38,333 $ 49.80 8.49 Options exercisable on December 31, 2023 29,583 $ 49.80 9.13 Weighted average fair value of options granted during the period - $ 27.60 -
Schedule of Warrant Activity	Warrant activity for the nine months ended September 30, 2024 is summarized as follows: Number of Weighted Weighted Aggregate Balance Outstanding, December 31, 2023 11,245 $ 54.78 4.13 $ - Granted 4,431,952 3.02 - - Exercised (1,777,101 ) 1.82 - - Balance Outstanding, September 30, 2024 2,666,096 $ 2.66 3.55 $ 4,239,093 Exercisable, September 30, 2024 2,666,096 $ 2.66 3.55 $ 4,239,093	Warrant activity for the year ended December 31, 2023 are summarized as follows: Number of Warrants Weighted Weighted Aggregate Balance Outstanding, December 31, 2022 - $ - - - Granted 11,245 54.78 - - Balance Outstanding, December 31, 2023 11,245 $ 54.78 4.13 - Exercisable, December 31, 2023 11,245 $ 54.78 4.13 -
Schedule of Placement Agent Warrants	The March 2024 Placement Agent Warrants were valued on the date of issuance using Binomial Lattice valuation model with the following assumptions: March 15, Dividend rate — % Term (in years) 5.5 years Volatility 186.5 % Risk—free interest rate 4.33 %
Schedule of Estimated Using the Binomial Option-Pricing Model	The fair value of the March 2024 Common Warrants on the modification date, the fair value of the New Warrants, and the fair value of the September 2024 Placement Agent Warrants were estimated using the Binomial option-pricing model with the following assumptions: September 20, Exercise price $2.33 to $3.225 Term (years) 1.75 to 5.5 Expected stock price volatility 162.4% Risk-free rate of interest 3.48% to 3.55%
Schedule of Grant Date Using a Black-Scholes Option Pricing Model	The stock options were valued at the grant date using a Black-Scholes option pricing model with the following assumptions: Nine Months Ended Nine Months Ended Dividend rate —% —% Term (in years) 3.0 to 6.0 years 3.0 to 6.0 years Volatility 168.9 to 184.6% 68.8% to 71.6% Risk—free interest rate 4.07% to 4.56% 3.95% to 4.00%

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Components of Deferred Tax Assets and Liabilities	As of December 31, 2023 and 2022, components of deferred tax assets and liabilities are as follows: December 31, December 31, Net operating loss carryforward $ 795,489 $ 190,123 Research and development 366,256 204,069 Total deferred tax assets 1,161,745 394,192 Valuation allowance (1,161,745 ) (394,192 ) Net Deferred Tax Assets $ - $ -
Schedule of Reconciliation of the Effective Tax Rate With the Statutory Federal Income Tax Rate	A reconciliation of the effective tax rate with the statutory Federal income tax rate was as follows for the years ended December 31, 2023 and 2022: For the For the Federal tax benefit at statutory rate (21.0 )% (21.0 )% State tax benefit, net of Federal tax benefit (5.1 )% (6.5 )% Non-deductible expenses 6.2 % - % Change in estimated effective tax rate (1.4 )% - % Change in valuation allowance 21.3 % 27.5 % Effective tax rate 0 % 0 %

Nature of Operations (Details)

Nature of Operations (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Nature of Operations (Details) [Line Items]
Reverse stock split	On March 7, 2024, the Company filed a Certificate of Amendment to the Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-12 reverse stock split with respect to the outstanding shares of the Company’s common stock.	1-for-12
Incorporation date	Oct. 27, 2021
Common Stock [Member]
Nature of Operations (Details) [Line Items]
Reverse stock split		On November 4, 2022, the Company filed a Certificate of Amendment to the Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-1.33 reverse stock split with respect to the outstanding shares of the Company’s common stock.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)			1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 13, 2024 USD ($) shares	Feb. 17, 2023 $ / shares shares	Feb. 17, 2023 USD ($) $ / shares shares	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($) $ / item	Dec. 31, 2022 USD ($)	Sep. 20, 2024 USD ($)	May 16, 2024 USD ($)	Dec. 31, 2021 USD ($)
Summary of Significant Accounting Policies [Line Items]
Cash				$ 5,227,894		$ 5,227,894		$ 1,024,710	$ 679,781
Short-term investments								2,592,689
Working capital				6,525,650		6,525,650		3,372,503
Net proceeds						159,060	$ 5,958,470	5,958,470
Deferred offering costs									202,599
Net cash in operations						(2,512,166)	(2,307,697)	(2,980,592)	(1,260,425)
Payments short-term investments						2,096,293	3,491,242	3,491,242
Net of offering costs										$ 30,979
FDIC limits				250,000		250,000		250,000
Accounts receivable								8
Unrealized (loss) income				$ 9,884	$ 41,841	(82,486)	79,646	95,785
Gain on sale of short-term investments						121,765		$ 20,662
Number of digital units (in Dollars per Item) | $ / item								1,553.37
Internal-use software development costs						$ 23,310	24,625	$ 56,971
Estimated useful life				5 years		5 years		5 years
Impairment loss							52,363	$ 52,363
Cash				5,227,894	764,977	5,227,894	764,977	1,024,710	679,781			$ 2,078,141
Short-term investments				1,416,056		1,416,056		2,592,689
Equity securities				$ 199,998		$ 199,998					$ 666,660
Units of polygon matic				52.78		52.78		1,553.37
Percentage of tax benefit						50%
Intangible Assets [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful life				5 years	5 years	5 years	5 years
Previously Reported [Member]
Summary of Significant Accounting Policies [Line Items]
Deferred offering costs									202,599
Dragon Interactive Corporation [Member]
Summary of Significant Accounting Policies [Line Items]
Equity securities				$ 666,660		$ 666,660					$ 199,998
Cash and Cash Equivalents [Member]
Summary of Significant Accounting Policies [Line Items]
Cash				$ 4,709,000		$ 4,709,000		$ 507,000
Intangible Assets [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful life								5 years
Forecast [Member]
Summary of Significant Accounting Policies [Line Items]
Common shares issued for cash (in Shares) | shares	47,128
IPO [Member]
Summary of Significant Accounting Policies [Line Items]
Common shares issued for cash (in Shares) | shares		140,563	140,563
Common stock price (in Dollars per share) | $ / shares		$ 49.8	$ 49.8
Aggregaye			$ 7,000,000
Net proceeds			5,958,470
Offering related expenses			$ 1,041,530
Deferred offering costs									202,599
Issuance costs									5,755,871
IPO [Member] | Previously Reported [Member]
Summary of Significant Accounting Policies [Line Items]
Deferred offering costs									$ 202,559
Private Placement [Member]
Summary of Significant Accounting Policies [Line Items]
Legal fees	$ 60,000
Private Placement [Member] | Forecast [Member]
Summary of Significant Accounting Policies [Line Items]
Common shares issued for cash (in Shares) | shares	108,000
Net proceeds	$ 3,056,984
Aggregate gross proceeds	3,499,484
Net of offering costs	382,500
Legal fees	$ 60,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Fair Value Hierarchy of its Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Level 1 [Member]
Schedule of Fair Value Hierarchy of its Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments	$ 1,416,056	$ 2,592,689
Level 2 [Member]
Schedule of Fair Value Hierarchy of its Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments
Level 3 [Member]
Schedule of Fair Value Hierarchy of its Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Computation of Diluted Shares Outstanding as they would have had an Anti-Dilutive Impact on the Company’s Net Loss (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Common stock equivalents:
Total anti-dilutive	2,730,180	49,578	49,578
Warrant [Member]
Common stock equivalents:
Total anti-dilutive	2,666,096	11,245	11,245
Stock options [Member]
Common stock equivalents:
Total anti-dilutive	64,084	38,333	38,333

Short-Term Investments and In_3

Short-Term Investments and Investment in Equity Securities (Details) - USD ($)	Sep. 30, 2024	May 16, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Short-Term Investments and Investment in Equity Securities (Details) [Line Items]
Investment in equity securities, at fair value	$ 199,998	$ 666,660
Short-Term Investments [Member]
Short-Term Investments and Investment in Equity Securities (Details) [Line Items]
Investment in equity securities, at fair value	$ 666,660	666,660
Dragon Interactive Corporation [Member]
Short-Term Investments and Investment in Equity Securities (Details) [Line Items]
Investment in equity securities, at fair value		$ 199,998

Short-Term Investments and In_4

Short-Term Investments and Investment in Equity Securities - Schedule of Short-Term Investments (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule of Short-Term Investments [Line Items]
Cost	$ 1,402,757	$ 2,496,904
Unrealized Gain	13,299	95,785
Fair Value	1,416,056	2,592,689
US Treasury Bills [Member]
Schedule of Short-Term Investments [Line Items]
Cost	1,402,757	2,496,904
Unrealized Gain	13,299	95,785
Fair Value	$ 1,416,056	$ 2,592,689

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Property and Equipment (Details) [Line Items]
Software development costs	$ 80,281		$ 80,281		$ 56,971
Amortized period	36 months		36 months
Software and Software Development Costs [Member]
Property and Equipment (Details) [Line Items]
Software development costs	$ 23,310	$ 24,625	$ 23,310	$ 24,625
Amortization of capitalized internal-use software development costs	$ 6,690	$ 684	$ 19,536	$ 684

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Property and Equipment [Abstract]
Capitalized internal-use software development costs, Useful life	3 years	3 years
Capitalized internal-use software development costs	$ 80,281	$ 56,971
Less: accumulated amortization	(23,901)	(4,365)
Property and equipment	$ 56,380	$ 52,606

Intangible Asset (Details)

Intangible Asset (Details) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 04, 2024	Aug. 29, 2022	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Intangible Asset [Line Items]
License fee		$ 25,000
Fees and expenses							$ 30,704
Professional fees							7,132
Initial financing gross proceeds							500,000
Intangible asset							52,363
Impairment loss						$ 52,363	52,363
Impairment loss			$ 7,500	$ 6,284	17,500	6,284	6,284
Purchase of intangible asset	$ 150,000				$ 150,000			$ 62,836
Purchase price amount	150,000
Installments amount	$ 37,500
Estimated useful life			5 years		5 years		5 years
Other Intangible Assets [Member]
Intangible Asset [Line Items]
Estimated useful life			5 years	5 years	5 years	5 years

Intangible Asset - Schedule of

Intangible Asset - Schedule of Intangible Asset (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Asset [Abstract]
License, Useful life	5 years	5 years
License	$ 150,000		$ 62,836
Less: accumulated amortization	(17,500)		(4,189)
Intangible asset	$ 132,500		$ 58,647

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)													1 Months Ended		3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 20, 2024	Jul. 17, 2024	May 28, 2024	Mar. 13, 2024	Mar. 07, 2024	Mar. 05, 2024	Mar. 20, 2023	Mar. 06, 2023	Mar. 06, 2023	Feb. 17, 2023	Feb. 14, 2023	Mar. 30, 2022	Feb. 17, 2023	Feb. 14, 2023	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Feb. 28, 2023	Jan. 31, 2022
Stockholders' Equity [Line Items]
Preferred stock, shares authorized															5,000,000						5,000,000		5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)															$ 0.0001						$ 0.0001		$ 0.0001	$ 0.0001
Preferred stock, shares issued
Preferred stock, shares outstanding
Subscriptions receivable (in Dollars)																										$ 37,500
Cancelled common stock shares																						105,931
Common stock exercise price (in Dollars per share)						$ 6
Gross proceeds (in Dollars)	$ 3,242,374
Net proceeds (in Dollars)	$ 2,834,843
Deferred offering costs (in Dollars)																								$ 202,599
Warrants issued	1,256,734														94,255						94,255
Warrants exercisable per share (in Dollars per share)	$ 2.58														$ 3.225						$ 3.225
Expire date																					Feb. 14, 2028
Shares reserved												208,333
Aggregate stock options shares		7,000	12,501					5,000	5,000		33,333			33,333
Stock options, expiration term																					Feb. 14, 2033		Feb. 14, 2033
Stock options, description																					The options vest as to (i) 28,333 of such options on February 14, 2023; and (ii) the remaining 5,000 options vest quarterly (417 each quarter) beginning on May 14, 2023 and each quarter thereafter through February 14, 2026.		The options vest as to (i) 28,333 of such options on February 14, 2023; and (ii) the remaining 5,000 options vest quarterly (417 each quarter) beginning on May 14, 2023 and each quarter thereafter through February 14, 2026.
Stock options valued (in Dollars)			$ 46,124					$ 33,972	$ 33,972		$ 1,023,290			$ 1,023,290
Stock-based compensation (in Dollars)																					$ 84,190	$ 914,426	$ 936,354
Balance remains future vesting periods (in Dollars)																					$ 131,258		$ 120,908
Weighted average period																					1 year 2 months 8 days		2 years 1 month 6 days
Aggregate intrinsic value (in Dollars)															$ 0						$ 0		$ 0
Purchase of common stock (in Dollars)																						$ 49,710
Average price per shares (in Dollars per share)																						$ 0.469
Sales of common stock (in Dollars)				$ 601,560
Sale of pre-funded warrants (in Dollars)																					2,897,924
Net proceed from common stock (in Dollars)																					$ 159,060	5,958,470	5,958,470
Percentage of gross proceeds cash fee																					7.50%
Percentage of management fee expense																					1%
Agent warrants (in Dollars)	$ 297,500
Percentage of wainwright fee expense																					7.50%
Percentage of common stock underlying warrant that were exercised																					7.50%
Agent fees (in Dollars)	376,552
Offering expenses (in Dollars)	$ 30,979
Exercise price (in Dollars per share)	$ 5.5
Clearing fees (in Dollars)																					$ 15,950
Percentage of common stock																					7.50%
Percentage of exercise price																					125%
Placement Agent Warrants															978,000						978,000
Net proceeds (in Dollars)															$ 417						$ 521
Percentage of shares outstanding												5%
Shares of stock options						6,249
Amount of aggregate fair value (in Dollars)						$ 33,880
Amount of annual cash fee proceed (in Dollars)					$ 40,000
Exercise price per share (in Dollars per share)			$ 3.82
Option vested percentage			25%
Grant date fair value of stock option (in Dollars)		$ 14,536
Stock-based expenses related to stock options (in Dollars)															$ 34,949	$ 33,435	$ 15,806	$ 21,927	$ 21,927	$ 870,572			$ 936,354
Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued																							11,245
Warrants exercisable per share (in Dollars per share)																							$ 54.78
Series A Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued															2,513,468						2,513,468
Warrant expire term																					five and one-half years
Series B Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued															1,256,734						1,256,734
Warrant expire term																					twenty-four months
Common Warrants [Member]
Stockholders' Equity [Line Items]
Net proceeds (in Dollars)	$ 2,834,843
Warrants issued															278,734						278,734
Warrants exercisable per share (in Dollars per share)															$ 2.58						$ 2.58
Pre-Funded Warrants [Member]
Stockholders' Equity [Line Items]
Warrants exercisable per share (in Dollars per share)															$ 0.001						$ 0.001
Sale of pre-funded warrants (in Dollars)				$ 2,897,924
Agent warrants (in Dollars)															$ 32,424						$ 32,424
Placement Agent Warrants															978,000						978,000
Common shares issued for warrant exercise															417,000	103,367
Net proceeds (in Dollars)																$ 104
Warrant [Member]
Stockholders' Equity [Line Items]
Warrants issued															978,000						978,000
Warrants exercisable per share (in Dollars per share)																	$ 5.5
Percentage of management fee expense																					1%
Agent warrants (in Dollars)															$ 243,178						$ 243,178
Placement Agent Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued				47,128											47,128						47,128
Warrants exercisable per share (in Dollars per share)															$ 6.9625						$ 6.9625
New Warrant [Member]
Stockholders' Equity [Line Items]
Warrants issued	2,513,468
Previously Reported [Member]
Stockholders' Equity [Line Items]
Deferred offering costs (in Dollars)																								202,599
Black-Scholes option [Member]
Stockholders' Equity [Line Items]
Dividend yield																							0%
Stock Options [Member]
Stockholders' Equity [Line Items]
Aggregate stock options shares																					25,750
Weighted average period
Stock-based expenses related to stock options (in Dollars)																					$ 84,190	$ 914,426
Stock Options [Member] | Previously Reported [Member]
Stockholders' Equity [Line Items]
Aggregate stock options shares																							38,333
Weighted average period
Minimum [Member]
Stockholders' Equity [Line Items]
Volatilities rate																							68.80%
Risk-free interest rates																							3.95%
Holding period																							3 years
Percentage of outstanding common stock after exercise																					4.99%
Maximum [Member]
Stockholders' Equity [Line Items]
Volatilities rate																							71.60%
Risk-free interest rates																							4%
Holding period																							6 years
Percentage of outstanding common stock after exercise																					9.99%
Common Stock [Member]
Stockholders' Equity [Line Items]
Common stock exercise price (in Dollars per share)								$ 49.8	$ 49.8		$ 49.8			$ 49.8
Warrants issued	1,256,734
Sale of common stock (in Dollars)				$ 601,560
Net proceed from common stock (in Dollars)				159,060
Common shares issued for warrant exercise															417,000	103,367
Stock-based expenses related to stock options (in Dollars)
Common Stock [Member] | Series A Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued	94,255														1,256,734						1,256,734
Common Stock [Member] | Warrant [Member]
Stockholders' Equity [Line Items]
Warrants issued															978,000						978,000
2023 Stock Repurchase Plan [Member]
Stockholders' Equity [Line Items]
Purchase of common stock (in Dollars)							$ 500,000																$ 99,736
Cancelled common stock shares																	6,846						20,349
Common stock, price per share (in Dollars)																							$ 4.9
Purchase of common stock (in Dollars)							$ 500,000										$ 19,602
Average price per shares (in Dollars per share)																	$ 2.86
Two Zero Two Two Equity Incentive Plan [Member]
Stockholders' Equity [Line Items]
Exercise price per share (in Dollars per share)		$ 2.15
Stock Options [Member]
Stockholders' Equity [Line Items]
Shares of stock options						2,083
H C Wainwright and Co LLC [Member]
Stockholders' Equity [Line Items]
Agent fees (in Dollars)																					$ 85,000
Medical Advisory Board [Member]
Stockholders' Equity [Line Items]
Shares of stock options					4,167
Stock Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued	1,256,734
Common Class B [Member]
Stockholders' Equity [Line Items]
Exercise price (in Dollars per share)															$ 2.33						$ 2.33
Series B Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued	1,256,734
Minimum [Member]
Stockholders' Equity [Line Items]
Shares reserved												95,304
Maximum [Member]
Stockholders' Equity [Line Items]
Shares reserved												303,637
IPO [Member]
Stockholders' Equity [Line Items]
Common stock issued										140,563			140,563
Common stock exercise price (in Dollars per share)													$ 49.8
Gross proceeds (in Dollars)										$ 7,000,000			$ 7,000,000
Net proceeds (in Dollars)										5,958,470			5,958,470
Net offering expenses (in Dollars)										$ 1,041,530			$ 1,041,530
Deferred offering costs (in Dollars)																								202,599
Warrants issued															11,245						11,245		11,245
Warrants exercisable per share (in Dollars per share)															$ 54.78						$ 54.78		$ 54.78
Expire date																					Feb. 14, 2028		Feb. 14, 2028
Fair value of these warrant (in Dollars)																					$ 3,657,258		$ 3,657,258
Dividend yield																					0%		0%
Volatilities rate																					69.80%		69.80%
Risk-free interest rates																					4.03%		4.03%
Holding period																					5 years		5 years
Common stock exercise price (in Dollars per share)										$ 49.8			$ 49.8
Net proceed from common stock (in Dollars)													$ 5,958,470
IPO [Member] | Previously Reported [Member]
Stockholders' Equity [Line Items]
Deferred offering costs (in Dollars)																								$ 202,559
Private Placement [Member]
Stockholders' Equity [Line Items]
Gross proceeds (in Dollars)				3,499,484
Net proceeds (in Dollars)				3,056,984
Net offering expenses (in Dollars)				$ 382,500
Common shares issued for cash				108,000
legal fees (in Dollars)				$ 60,000
Percentage of gross proceeds cash fee																					7.50%
Percentage of management fee expense																					1%
Agent warrants (in Dollars)															$ 318,900						$ 318,900
Private Placement [Member] | Series A Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued				628,367
Private Placement [Member] | Series B Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued				628,367
Private Placement [Member] | Common Warrants [Member]
Stockholders' Equity [Line Items]
Gross proceeds (in Dollars)				$ 601,560
Warrants exercisable per share (in Dollars per share)				$ 5.57
Private Placement [Member] | Pre-Funded Warrants [Member]
Stockholders' Equity [Line Items]
Gross proceeds (in Dollars)				$ 2,897,924
Warrants issued				520,367
Warrants exercisable per share (in Dollars per share)				$ 5.569
Stock Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued				1,256,734																					11,245
Agent warrants (in Dollars)	$ 5,460,000
Stock Warrants [Member] | Warrants [Member]
Stockholders' Equity [Line Items]
Warrants exercisable per share (in Dollars per share)															$ 54.78						$ 54.78
Stock Warrants [Member] | Series A Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued				628,367
Stock Warrants [Member] | Series B Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued				628,367
Stock Warrants [Member] | Pre-Funded Warrants [Member]
Stockholders' Equity [Line Items]
Warrants issued				520,367

Stockholders_ Equity - Schedule

Stockholders’ Equity - Schedule of Option Activity (Details) - Stock Option [Member] - Previously Reported [Member]		12 Months Ended
	Dec. 31, 2022 $ / shares shares	Dec. 31, 2023 $ / shares shares
Schedule of Total Stock-Based Expenses Related to Stock Options [Line Items]
Number of Options, Ending balance | shares		38,333
Weighted Average Exercise Price, Ending balance | $ / shares		$ 49.8
Weighted Average Remaining Contractual Life (Years), Ending balance		8 years 5 months 26 days
Number of Options, Options exercisable | shares		29,583
Weighted Average Exercise Price, Options exercisable | $ / shares		$ 49.8
Weighted Average Remaining Contractual Life (Years), Options exercisable		9 years 1 month 17 days
Number of Options, Weighted average fair value of options granted during the period | shares
Weighted Average Exercise Price, Weighted average fair value of options granted during the period | $ / shares		$ 27.6
Weighted Average Remaining Contractual Life (Years), Weighted average fair value of options granted during the period
Number of Options, Granted | shares		38,333
Weighted Average Exercise Price, Granted | $ / shares		$ 49.8
Weighted Average Remaining Contractual Life (Years), Granted

Stockholders_ Equity - Schedu_2

Stockholders’ Equity - Schedule of Warrant Activity (Details) - Stock Warrants [Member] - USD ($)			9 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Number of Warrants, Ending balance	11,245		2,666,096	11,245
Weighted Average Exercise Price, Ending balance	$ 54.78		$ 2.66	$ 54.78
Weighted Average Remaining Contractual Term (Years), Ending balance	4 years 1 month 17 days		3 years 6 months 18 days	4 years 1 month 17 days
Aggregate Intrinsic Value, Ending balance			$ 4,239,093
Number of Warrants, Exercisable	11,245		2,666,096	11,245
Weighted Average Exercise Price, Exercisable	$ 54.78		$ 2.66	$ 54.78
Weighted Average Remaining Contractual Term (Years), Exercisable			3 years 6 months 18 days	4 years 1 month 17 days
Aggregate Intrinsic Value, Exercisable			$ 4,239,093
Number of Warrants, Granted			4,431,952	11,245
Weighted Average Exercise Price, Granted			$ 3.02	$ 54.78
Weighted Average Remaining Contractual Term (Years), Granted
Aggregate Intrinsic Value, Granted

Commitments and Contingencies (

Commitments and Contingencies (Details)	Feb. 17, 2023 USD ($) shares
Mr. Mats [Member]
Commitments and Contingencies [Line Items]
Base salary | $	$ 400,000
Mr. Mats [Member]
Commitments and Contingencies [Line Items]
Base salary | $	$ 400,000
Shares of common stock | shares	16,667
2022 Equity Incentive Plan [Member] | Mr. Mats [Member]
Commitments and Contingencies [Line Items]
Shares of common stock | shares	16,667

Income Taxes (Details)

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2023 USD ($)
Income Taxes (Details) [Line Items]
Net operating loss carry forwards	$ 3,043,768
Federal net operating loss carry forwards	$ 3,043,768
Taxable income percentage	80%
Effective tax rate	26.135%
Valuation allowance	$ 1,161,745
Valuation allowance increased	$ 767,553
Domestic Research [Member]
Income Taxes (Details) [Line Items]
Amortize research and development	5%
Foreign Research [Member]
Income Taxes (Details) [Line Items]
Amortize research and development	15%

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Components of Deferred Tax Assets and Liabilities [Abstract]
Net operating loss carryforward	$ 795,489	$ 190,123
Research and development	366,256	204,069
Total deferred tax assets	1,161,745	394,192
Valuation allowance	(1,161,745)	(394,192)
Net Deferred Tax Assets

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of the Effective Tax Rate With the Statutory Federal Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Reconciliation of The Effective Tax Rate With The Statutory Federal Income Tax Rate [Abstract]
Federal tax benefit at statutory rate	(21.00%)	(21.00%)
State tax benefit, net of Federal tax benefit	(5.10%)	(6.50%)
Non-deductible expenses	6.20%
Change in estimated effective tax rate	(1.40%)
Change in valuation allowance	21.30%	27.50%
Effective tax rate	0%	0%

Subsequent Events (Details)

Subsequent Events (Details)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Jul. 17, 2024 shares

May 28, 2024 shares

Mar. 13, 2024 USD ($) $ / shares shares

Mar. 07, 2024 USD ($) shares

Mar. 05, 2024 $ / shares shares

Mar. 04, 2024 USD ($)

Mar. 06, 2023 shares

Mar. 06, 2023 shares

Feb. 14, 2023 shares

Feb. 14, 2023 shares

Mar. 31, 2024 USD ($) $ / shares

Mar. 28, 2024 USD ($) $ / shares shares

Sep. 30, 2023 USD ($)

Jun. 30, 2023 USD ($)

Sep. 30, 2024 USD ($) $ / shares shares

Sep. 30, 2023 USD ($)

Dec. 31, 2023 USD ($)

Dec. 31, 2022 USD ($)

Sep. 23, 2024

Sep. 20, 2024 USD ($) $ / shares shares

Subsequent Events [Line Items]

Reverse stock split of shares issued and outstanding

On March 7, 2024, the Company filed a Certificate of Amendment to the Amended and Restated Articles of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to effect a 1-for-12 reverse stock split with respect to the outstanding shares of the Company’s common stock.

1-for-12

Granted stock options

7,000

12,501

5,000

5,000

33,333

33,333

Exercise price, per share | $ / shares

$ 6

Stock options expiried date

Feb. 14, 2033

Feb. 14, 2033

Net proceeds | $

$ 159,060

$ 5,958,470

$ 5,958,470

Net of offering costs | $

$ 30,979

Exercise price, per share | $ / shares

$ 3.225

$ 2.58

Gross proceeds | $

3,500,000

Cancelled shares | $

$ 19,602

$ 25,469

$ 24,241

$ 99,736

Warrant shares

94,255

1,256,734

Series A Warrants [Member]

Subsequent Events [Line Items]

Warrant shares

2,513,468

Series B Warrants [Member]

Subsequent Events [Line Items]

Warrant shares

1,256,734

Pre-Funded Warrants [Member]

Subsequent Events [Line Items]

Exercise price, per share | $ / shares

$ 0.001

Common Warrants [Member]

Subsequent Events [Line Items]

Exercise price, per share | $ / shares

$ 2.58

Warrant shares

278,734

Warrant [Member]

Subsequent Events [Line Items]

Exercise price, per share | $ / shares

$ 5.5

Warrant shares

978,000

Minimum [Member]

Subsequent Events [Line Items]

Percentage of membership interest

30%

Maximum [Member]

Subsequent Events [Line Items]

Percentage of membership interest

70%

Board of Directors [Member]

Subsequent Events [Line Items]

Reverse stock split of shares issued and outstanding

one share of common stock for each 12 shares of the Company’s common stock

Private Placement [Member]

Subsequent Events [Line Items]

Legal fees | $

$ 60,000

Private Placement [Member] | Series A Warrants [Member]

Subsequent Events [Line Items]

Warrant shares

628,367

Private Placement [Member] | Series B Warrants [Member]

Subsequent Events [Line Items]

Warrant shares

628,367

Private Placement [Member] | Pre-Funded Warrants [Member]

Subsequent Events [Line Items]

Exercise price, per share | $ / shares

$ 5.569

Warrant shares

520,367

Private Placement [Member] | Common Warrants [Member]

Subsequent Events [Line Items]

Exercise price, per share | $ / shares

$ 5.57

Forecast [Member]

Subsequent Events [Line Items]

Aggregate purchase price | $

$ 150,000

Monthly installments

4

Monthly installments payable | $

$ 37,500

Granted stock options

6,249

Exercise price, per share | $ / shares

$ 6

Stock options expiried date

Mar. 05, 2029

Stock options granted date

Mar. 05, 2025

Cash fee | $

$ 40,000

Purchase shares

47,128

Common stock purchase, shares

6,846

Aggregate gross proceeds | $

$ 601,560

Exercise price, per share | $ / shares

$ 5.5

Cash fee percentage

7.50%

Management fee percentage

1%

Engagement letter description.

the Company shall (i) pay Wainwright a cash fee of 7.5% and a management fee of 1.0% of the aggregate gross exercise paid in cash with respect thereto, and (ii) issue warrants to purchase that number of shares of common stock equal to 7.5% of the aggregate number of shares of common stock underlying the warrants that were exercised.

Cancelled shares | $

$ 19,601

Average price, per share | $ / shares

$ 2.86

Forecast [Member] | Pre-Funded Warrants [Member]

Subsequent Events [Line Items]

Owned percentage

4.99%

Forecast [Member] | Common Warrants [Member]

Subsequent Events [Line Items]

Owned percentage

9.99%

Forecast [Member] | Medical Advisory Board [Member]

Subsequent Events [Line Items]

Purchase shares

4,167

Forecast [Member] | Director [Member]

Subsequent Events [Line Items]

Granted stock options

2,083

Forecast [Member] | Private Placement [Member]

Subsequent Events [Line Items]

Purchase shares

108,000

Purchase price, per unit | $ / shares

$ 5.57

Aggregate gross proceeds | $

$ 3,499,484

Shares sold

520,367

Purchase price of each pre-funded warrant

5.569

Net proceeds | $

$ 3,056,984

Net of offering costs | $

382,500

Legal fees | $

$ 60,000

Exercise price, per share | $ / shares

$ 0.001

Forecast [Member] | Private Placement [Member] | Series A Warrants [Member]

Subsequent Events [Line Items]

Common stock purchase, shares

628,367

Forecast [Member] | Private Placement [Member] | Series B Warrants [Member]

Subsequent Events [Line Items]

Common stock purchase, shares

628,367

Forecast [Member] | Pre-Funded Warrants [Member]

Subsequent Events [Line Items]

Aggregate gross proceeds | $

$ 2,897,924

Forecast [Member] | Placement Agent Warrants [Member]

Subsequent Events [Line Items]

Exercise price, per share | $ / shares

$ 6.9625

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Level 1 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments	$ 1,416,056	$ 2,592,689
Equity securities
Level 2 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments
Equity securities
Level 3 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis [Line Items]
Short-term investments
Equity securities	$ 199,998

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Schedule of Investment in Equity Securities, at Fair Value for the Periods (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Investment in Equity Securities, at Fair Value for the Periods [Abstract]
Balance, beginning of period
Additions	199,998
Balance, end of period	$ 199,998

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Schedule of Computation of Diluted Shares Outstanding (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Schedule of Computation of Diluted Shares Outstanding [Line Items]
Total anti-dilutive	2,730,180	49,578	49,578
Warrants [Member]
Schedule of Computation of Diluted Shares Outstanding [Line Items]
Total anti-dilutive	2,666,096	11,245	11,245
Stock options [Member]
Schedule of Computation of Diluted Shares Outstanding [Line Items]
Total anti-dilutive	64,084	38,333	38,333

Short-Term Investments and In_5

Short-Term Investments and Investment in Equity Securities - Schedule of Short-Term Investments (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Schedule of Short-Term Investments [Line Items]
Cost	$ 1,402,757	$ 2,496,904
Cumulative Unrealized Loss	13,299	95,785
Fair Value	1,416,056	2,592,689
US Treasury Bills [Member]
Schedule of Short-Term Investments [Line Items]
Cost	1,402,757	2,496,904
Cumulative Unrealized Loss	13,299	95,785
Fair Value	$ 1,416,056	$ 2,592,689

Short-Term Investments and In_6

Short-Term Investments and Investment in Equity Securities - Schedule of Investment in Equity Securities, at Fair Value for the Periods (Details) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Schedule of Short-Term Investments [Line Items]
Balance, beginning of period
Additions	199,998
Balance, end of period	$ 199,998

Property and Equipment - Sche_2

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Property and Equipment [Abstract]
Capitalized internal-use software development costs, Useful life	3 years	3 years
Capitalized internal-use software development costs	$ 80,281	$ 56,971
Less: accumulated amortization	(23,901)	(4,365)
Property and equipment	$ 56,380	$ 52,606

Intangible Asset - Schedule o_2

Intangible Asset - Schedule of Intangible Asset (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Asset [Abstract]
License, Useful life	5 years	5 years
License	$ 150,000		$ 62,836
Less: accumulated amortization	(17,500)		(4,189)
Intangible asset	$ 132,500		$ 58,647

Intangible Asset - Schedule o_3

Intangible Asset - Schedule of Amortization of the Intangible Asset (Details) - USD ($)	Sep. 30, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Amortization of the Intangible Asset [Abstract]
2025	$ 30,000
2026	30,000
2027	30,000
2028	30,000
2029	12,500
Intangible asset	$ 132,500		$ 58,647

Stockholders_ Equity - Schedu_3

Stockholders’ Equity - Schedule of Placement Agent Warrants (Details) - Placement Agent Warrants [Member]	Mar. 15, 2024
Dividend rate [Member]
Schedule of Placement Agent Warrants [Line Items]
Warrants and rights outstanding, measurement input
Term [Member]
Schedule of Placement Agent Warrants [Line Items]
Warrants and rights outstanding, measurement input, term	5 years 6 months
Volatility [Member]
Schedule of Placement Agent Warrants [Line Items]
Warrants and rights outstanding, measurement input	186.5
Risk free interest rate [Member]
Schedule of Placement Agent Warrants [Line Items]
Warrants and rights outstanding, measurement input	4.33

Stockholders_ Equity - Schedu_4

Stockholders’ Equity - Schedule of Estimated Using the Binomial Option-Pricing Model (Details)	Sep. 20, 2024
Exercise price [Member] | Minimum [Member]
Schedule of Estimated Using the Binomial Option-Pricing Model [Line Items]
Common warrants fair value	2.33
Exercise price [Member] | Maximum [Member]
Schedule of Estimated Using the Binomial Option-Pricing Model [Line Items]
Common warrants fair value	3.225
Term (years) [Member] | Minimum [Member]
Schedule of Estimated Using the Binomial Option-Pricing Model [Line Items]
Common warrants fair value , term	1 year 9 months
Term (years) [Member] | Maximum [Member]
Schedule of Estimated Using the Binomial Option-Pricing Model [Line Items]
Common warrants fair value , term	5 years 6 months
Expected stock price volatility [Member]
Schedule of Estimated Using the Binomial Option-Pricing Model [Line Items]
Common warrants fair value	162.4
Risk-free rate of interest [Member] | Minimum [Member]
Schedule of Estimated Using the Binomial Option-Pricing Model [Line Items]
Common warrants fair value	3.48
Risk-free rate of interest [Member] | Maximum [Member]
Schedule of Estimated Using the Binomial Option-Pricing Model [Line Items]
Common warrants fair value	3.55

Stockholders_ Equity - Schedu_5

Stockholders’ Equity - Schedule of Warrant Activity (Details) - Stock Warrants [Member] - USD ($)			9 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2024	Dec. 31, 2023
Schedule of Warrant Activity [Line Items]
Number of Warrants, Ending balance	11,245		11,245
Weighted Average Exercise Price, Ending balance	$ 54.78		$ 54.78
Weighted Average Remaining Contractual Term (Years), Ending balance	4 years 1 month 17 days		3 years 6 months 18 days	4 years 1 month 17 days
Aggregate Intrinsic Value, Ending balance
Number of Warrants, Exercisable	11,245		2,666,096	11,245
Weighted Average Exercise Price, Exercisable	$ 54.78		$ 2.66	$ 54.78
Weighted Average Remaining Contractual Term (Years), Exercisable			3 years 6 months 18 days	4 years 1 month 17 days
Aggregate Intrinsic Value, Exercisable			$ 4,239,093
Number of Warrants, Granted			4,431,952	11,245
Weighted Average Exercise Price, Granted			$ 3.02	$ 54.78
Weighted Average Remaining Contractual Term (Years), Granted
Aggregate Intrinsic Value, Granted
Number of Warrants, Exercised			(1,777,101)
Weighted Average Exercise Price, Exercised			$ 1.82
Weighted Average Remaining Contractual Term (Years), Exercised
Aggregate Intrinsic Value, Exercised
Number of Warrants, Ending balance	11,245		2,666,096	11,245
Weighted Average Exercise Price, Ending balance	$ 54.78		$ 2.66	$ 54.78
Aggregate Intrinsic Value, Ending balance			$ 4,239,093

Stockholders_ Equity - Schedu_6

Stockholders’ Equity - Schedule of Grant Date Using a Black-Scholes Option Pricing Model (Details)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Dividend rate [Member]
Schedule of Grant Date Using a Black-Scholes Option Pricing Model [Line Items]
Dividend rate
Term (in years) [Member] | Minimum [Member]
Schedule of Grant Date Using a Black-Scholes Option Pricing Model [Line Items]
Term (in years)	3 years	3 years
Term (in years) [Member] | Maximum [Member]
Schedule of Grant Date Using a Black-Scholes Option Pricing Model [Line Items]
Term (in years)	6 years	6 years
Volatility [Member] | Minimum [Member]
Schedule of Grant Date Using a Black-Scholes Option Pricing Model [Line Items]
Volatility	168.90%	68.80%
Volatility [Member] | Maximum [Member]
Schedule of Grant Date Using a Black-Scholes Option Pricing Model [Line Items]
Volatility	184.60%	71.60%
Risk—free interest rate [Member] | Minimum [Member]
Schedule of Grant Date Using a Black-Scholes Option Pricing Model [Line Items]
Risk—free interest rate	4.07%	3.95%
Risk—free interest rate [Member] | Maximum [Member]
Schedule of Grant Date Using a Black-Scholes Option Pricing Model [Line Items]
Risk—free interest rate	4.56%	4%

Stockholders_ Equity - Schedu_7

Stockholders’ Equity - Schedule of Option Activity (Details) - Stock Option [Member] - $ / shares		9 Months Ended
	Dec. 31, 2023	Sep. 30, 2024
Schedule of Option Activity [Line Items]
Number of Options, Ending balance	38,334	64,084
Weighted Average Exercise Price, Ending balance	$ 49.8	$ 31.35
Weighted Average Remaining Contractual Life (Years), Ending balance	8 years 5 months 26 days	8 years 3 days
Number of Options, Options exercisable		38,960
Weighted Average Exercise Price, Options exercisable		$ 46.11
Weighted Average Remaining Contractual Life (Years), Options exercisable		7 years 10 months 6 days
Number of Options, Weighted average fair value of options granted during the period
Weighted Average Exercise Price, Weighted average fair value of options granted during the period		$ 3.67
Weighted Average Remaining Contractual Life (Years), Weighted average fair value of options granted during the period
Number of Options, Granted		25,750
Weighted Average Exercise Price, Granted		$ 3.9
Weighted Average Remaining Contractual Life (Years), Granted